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Rett Syndrome is a severe neurological disorder caused by mutations in the 
X-chromosome-linked MECP2 gene, which encodes the transcription factor 
methyl-CpG binding protein 2 (MeCP2). Symptoms become obvious during early 
childhood and include life-threatening breathing abnormalities accompanied by 
severe periods of apnea causing intermitted hypoxia and frequently sudden death. 
Gene expression analysis in MeCP2 deficient mice revealed a pathologically strong 
expression in the gene encoding for the serotonin receptor 5B (5-HTR5B) in the 
ventral respiratory group (VRG), which includes the region important for respiratory 
rhythm generation. 
Extensive protein analysis showed that 5-HTR5B is naturally truncated and displayed 
an unusual intracellular localization on tubular and vesicular membranes. Despite 
truncation, the protein is able to bind inhibitory G-proteins, which consequently 
decreases intracellular cAMP concentration. In MeCP2 knockout mice the persistent 
cAMP reduction in the VRG caused disturbed breathing. Mice, which additionally lack 
the Htr5b gene, revealed normal respiratory network output activity. Moreover, these 
double-knockout mice appeared healthier concerning bodyweight and size and 
showed extended lifespan.  
Administration of forskolin, an adenylyl cyclase activator that elevates intracellular 
cAMP concentration, normalized breathing in MeCP2 deficient mice. Therefore, the 
application of cAMP elevating drugs might be an effective pharmacological strategy 
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‘What do you want, boy or girl?’ An expectant mother asks her husband. ‘I don’t 
mind, the main thing is our child will be healthy’. That is the answer of almost all 
expectant parents. But for 1 in 10,000 newborn girls these wishes don’t come true 
when the girls are diagnosed with Rett syndrome. 
 
1.1. Rett syndrome 
Rett syndrome (RTT) first described by the Vienna physician Andreas Rett (Rett, 
1966) has been classified as a progressive neurodevelopmental disorder 
(International Statistical Classification of Diseases and Related Health Problems 
(ICD-10): F84.10) caused by different mutations in the X-chromosome-linked MECP2 
gene (Amir et al., 1999). It attracted attention by the medical community as Hagberg 
and colleagues reported 38 cases from girls (Hagberg et al., 1983). With an 
estimated evidence of 1 in 10,000 - 15,000 at an age of 32, RTT is the second most 
common cause for mental retardation after Down syndrome in female (Hagberg, 
1985; Percy & Lane, 2004; Fehr et al., 2011). 
Affected children apparently develop normal. After six to 18 months of age, 
stagnation occurs (Stage I) followed by a period of rapid developmental regression 
(Stage II) where the children lose some of already learned skills, such as walking and 
purposeful hand use. This phase is accompanied with the onset of deceleration of 
head growth, which leads to microcephaly by the second year of life (Hagberg et al., 
1983). The accelerated loss of communication skills and mobility leads to apathetic 
behavior and social unresponsiveness (Nomura, 2005). Other autistic features such 
as expressionless face, lack of eye-to-eye contact and social smiling as well as 
hypersensitivity to sound become obvious between the regression period, but is less 
noticeable after school age at a pseudo stationary period (Stage III) (Zappella, 1997; 
Gillberg, 1986). Characteristic features are also stereotypic hand movements, teeth 
grinding, night crying, anxiety, and physical complaints, such as gait apraxia, ataxia, 
dystonia, seizures, severe constipation, oropharyngeal dysfunctions, cardiac 
abnormalities, osteopenia, and disturbed breathing (Mount et al., 2001; Steffenburg 
et al., 2001; Hagberg et al., 1983). Despite having a normal appetite, patients lose 




The last stage is accompanied by accelerated motor deterioration (stage IV). Patients 
who reached higher age are often wheelchair bound, which in many cases results in 
scoliosis. Some patients develop motor symptoms characteristic for Parkinson’s 
disease (Hagberg, 2005; Roze et al., 2007). Although the mortality rate increases 
1.2% per annum, some RTT patients survive into the sixth or seventh decade (Kerr 
et al., 1997; Zoghbi et al., 2007). 
 
1.1.1. Disturbed breathing in Rett syndrome 
One of the most prominent and striking features is disturbed breathing rhythm. More 
than half of the RTT patients show breathing irregularities such as forced and deep 
breathing, air swallowing, Valsalva’s maneuvers, breath holding, hyperventilation and 
apneustic breathing during wakefulness (Lugaresi et al., 1985; Elian et al., 1991; 
Glaze et al., 1987) as well as during sleep (Rohdin et al., 2007). 
About 25% of them show clinically relevant phases of apnea lasting longer than 45 
seconds that often occur after hypocapnia caused by hyperventilation (Kerr & Julu, 
1999; Schlüter et al., 1995; Kerr et al., 1990).  
During apnea, oxygen saturation can drop to life-threatening 50% of normal (Southall 
et al., 1988; Marcus et al., 1994), which may contribute to sudden death in 25% of 
RTT patients (Weese-Mayer et al., 2008; Smeets et al., 2012; Kerr & Engerström, 
2001).  
Early on, respiratory dysfunction was associated with an impaired serotonergic 
modulation depending on the immaturity of brainstem neurons (Kerr & Julu, 1999; 
Julu et al., 1997; Rhodin et al., 2007; Smeets et al., 2006).  
 
1.1.2. Genetic background 
95% of patients with classical RTT carry mutations in the MECP2 gene. The gene 
resides on the X-chromosome (Xq28) and codes for the methyl-CpG binding protein 
2 (MeCP2), which was discovered by selective binding to symmetrical 5’-methylated 
cytosines within a single CpG dinucleotide (Lewis et al., 1992; Meehan et al., 1992; 
D’Esposito et al., 1996).  
Most of these MECP2 mutations emerge sporadically in the male germ line and 
hence are inherited from the father (Trappe et al., 2001). Over the past few years 
more than 2,000 different MECP2 mutations varying from missense, nonsense, and 
frame shift mutations as well as larger deletions and insertions have been reported 
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(Amano et al., 2000; Hampson et al., 2000; Xiang et al., 2000; Archer et al., 2006; 
Bienvenu et al., 2000; Laccone et al., 2004; Philippe et al., 2006). However, eight 
mutations, which are mostly caused by CT transversions, occur more frequently 
(Bienvenu & Chelly, 2007; Wan et al., 1999).  
The gonosomal localization of MECP2 is causal for the gynecotropism of the 
disease. As the majority of X-chromosomal genes, MECP2 is subject to X-
chromosome inactivation (XCI). XCI due to gene dosage compensation leads to a 
mosaic expression pattern of MECP2 in hemizygotic females. The partial 
compensation of the mutated MECP2 allele in turn leads to survival of affected 
females. 
Since the discovery of the genetic cause, there are increasing reports of males 
diagnosed with RTT that exhibit either a mild form of MECP2 mutation or an unusual 
XXY-karyotype known as Klinefelter syndrome (Jan et al., 1999; Meloni, 2000; 
Schwartzman et al., 2001; Budden et al., 2005; Mittal et al., 2011; Dayer et al., 2007). 
Males with dire mutations of MECP2 rarely live beyond 2 years. In one such case, 
the patient, 16 months of age, succumbed to respiratory failure (Schüle et al., 2008). 
In females there are ongoing attempts to correlate the degree of MECP2 mutation 
with the severity of the RTT phenotype.  
Missense mutations or mutations affecting the C-terminal end of the MeCP2 protein 
lead to a less severe RTT phenotype than nonsense mutations in its N-terminal 
region or frame shift mutations (Zapella et al., 2001; Charman et al., 2005; Cheadle 
et al., 2000). The nonsense mutation Arg270X (codon that codes for arginine at place 
270 of the protein) has been associated with increased mortality (Jian et al., 2005).  
Another major source for phenotype variability is the XCI pattern, which has been 
shown by monozygotic twins who carry identical MECP2 mutations, but exhibit 
different phenotypes (Coleman et al., 1987; Migeon et al., 1995).  
The choice of either the maternal or the paternal X chromosome that will be 
inactivated normally happens in a random fashion during female embryogenesis and 
is maintained in descendent cells throughout the lifetime. However, in female patients 
as well as in mouse models for RTT, a skewed XCI has been observed (Wan et al., 
1999; Migeon et al., 1995; Braunschweig et al., 2004; Chahrour & Zoghbi, 2007; Ishii 
et al., 2001). The investigators showed that the X-chromosome, which carries the 
mutated MECP2 gene, is inactivated more frequently than the chromosome that 
INTRODUCTION 
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carries the healthy MECP2 copy. According to the authors, this effect might be 
caused by a positive selection and may explain milder forms of RTT.  
 
1.1.3. The methyl-CpG binding protein 2 - MeCP2 
The human MECP2 gene and the mouse ortholog Mecp2 reside on the X-
chromosome and consist of 4 exons (Quaderi et al., 1994; D’Esposito et al., 1996). 
Alternative polyadenylation within the 3’-untranslated region (UTR) of the fourth exon 
leads to 4 differentially expressed mRNAs varying in their size, but not in their open 
reading frame (D’Esposito et al., 1996; Reichwald et al., 2000). The shortest 1.8 kb 
and especially the longest 10.2 kb transcripts are more abundantly expressed in the 
brain than the 5.4 kb and the 7.2 kb-transcript, which are the predominant forms in 
the lung and the spleen (Pelka et al., 2005; Shahbazian et al., 2002a). In 2004, a 
second MeCP2 isoform was discovered encoded by the Mecp2e1 mRNA, which is 
generated by alternative splicing of the exon 2. The lack of exon 2 of the Mecp2e1 
mRNA results in a protein with 498 aa. Hence, it is 21 amino acids larger and 
possesses a changed N-terminus in comparison with the protein, which is encoded 
by the Mecp2e2 transcript (Mnatzakanian et al., 2004; Kriaucionis & Bird, 2004).  
With 90%, the Mecp2e1 transcript represents the dominant form in the brain, where it 
is basically strongly expressed in comparison to other organs and tissues. Smaller 
amounts of the Mecp2 mRNA have also been proven in the lung, thymus as well as 
in the spleen (Kriaucionis & Bird, 2004). 
The well characterized human MeCP2 protein (fig. 1.1) consists of an N-terminal 
methyl-CpG binding domain and a C-terminal repression domain (TRD) (Nan et al. 
1993; Nan et al., 1997). By means of an internal nuclear localization sequence 
(NLS), which resides within the TRD (Nan et al., 1996), it is transported into the cell 
nucleus. There it binds preferably to symmetrically methylated cytosines within a 
single CpG dinucleotide (Lewis et al., 1992; Meehan et al., 1992). By means of the 
co-repressor Sin3a (Nan et al., 1998), MeCP2 can recruit histone deacetylases 
(HDACs) that is commonly known as a starting point for chromatin remodeling and 
for densely packed DNA formation, called heterochromatin. Heterochromatin 
formation is closely linked to silencing of genes, chromosomal segments, and even 
whole chromosomes, hence, it regulates epigenetical processes, such as imprinting, 
position effect, histone code, X-chromosomal inactivation, maternal effects, etc. 
(Boyes and Bird, 1991; Kass et al., 1997; Henikoff, 2000).  
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The role of MeCP2 in epigenetical gene silencing has been strengthened by studies 
showing that MeCP2 is primarily located in heterochromatic DNA foci, such as 
satellite DNA, centromeres and telomeres and that it can directly repress the 
transcription of selected genes, e.g. UBE3A, GABRB3, Crh, Fkbo5 and Bdnf (Nan et 
al., 1997b; Samaco et al., 2009; Nuber et al., 2005; Chen et al., 2003; Martinowich et 
al., 2003). Furthermore MeCP2 can inhibit the expression and transposition of 
retrotransposons in a methyl-CpG dependent manner (Muotri et al., 2010).  
It has also been shown that MeCP2 can bind to non-methylated DNA as well as to 
whole nucleosomes directly. Because in a single cell the number of MeCP2 protein 
copies is as abundantly expressed as nucleosomes exist and MeCP2 can even 
replace the histone 1 within a histone octamer, it would seem that MeCP2 is more a 
global regulator than a simple transcriptional repressor. The theory is underscored by 
microarray analyses from different brain regions comparing mRNA expression 
between Mecp2 ko and wt mice. Many genes have been shown to be de-regulated 
(Jordan et al., 2007; Urdinguio et al., 2008; Ben-Shachar et al., 2009; Chahrour et al., 
2008). Surprisingly, most of them were down-regulated in the absence of MeCP2. 
Several genes, such as Sst, Oprk1, and Gprin1 are directly activated by MeCP2 
through a direct interaction with the transcriptional activator cAMP responsive 
element binding protein 1 (CREB1) (Chahrour et al., 2008).  
Although MeCP2 is considered to be important during brain development, it is most 
abundantly accumulated in postmitotic adult neurons, where it is thought to be 
indispensible for maturation, synaptogenesis, and the maintenance of neuronal 
function (Kishi & Macklis, 2004; Guy et al., 2011). Smaller amounts of MeCP2 are 














Figure 1.1. Schematic representation of the human methyl-CpG protein 2 (MeCP2) protein with 
potential binding partners and their function.  
The protein consists of 486 amino acids and possesses a N-terminal CpG-binding domain, a C-
terminal transcription repression domain (TRD), and a nuclear localization sequence (NLS). Horizontal 
lines show the binding region of identified interaction protein partners and their function on the right. 
Dashed lines indicate that interaction region is not defined yet. S80 and S421 indicate serine residues 
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1.1.4. The mouse model of Rett syndrome 
The transcription factor MeCP2 is of particular interest, not only as a single gene 
responsible for the complex RTT disorder with its broad spectrum of symptoms, but 
also in its role of modulating epigentical processes.  
Pathological effects on the murine brain due to Mecp2 mutations could help to 
identify genes involved in fundamental neurophysiological and molecular processes 
that are currently poorly understood. Therefore, various mouse models have been 
developed (Shahbazian et al., 2002b; Dani et al., 2005; Chahrour et al., 2008; Chen 
et al., 2001; Guy et al., 2001; Guy et al., 2007; Goffin et al., 2012). 
In this study, male Mecp2-/y mice with a knockout of Mecp2 (Rett mice), which are 
maintained on a C57BL/6 background and generated by Guy and colleagues in 2001 
using Cre-loxP technology, was used as animal model for RTT pathology.  
This mouse model displays many RTT-related motor disturbances within a relative 
developmental time frame that corresponds to the human disorder. Similar to RTT 
patients, Mecp2-/y mice show no initial disturbed phenotype. Between postnatal day 
(P) 14 and P21 they start to develop a stiff and uncoordinated gait produced mainly 
in the hind limbs.   
Almost all Mecp2-/y mice show reduced body and brain weight relative to wt mice. 
These mice are less mobile and unresponsive to external stimuli, frequently exhibit 
hind limb clasping and tremor, and are in poor general condition before dying at 
approximately 54 days of age (Chen et al., 2001; Guy et al., 2007). At autopsy, 
brains are smaller and lighter. Neuronal cell bodies and nuclei are reduced in the 
hippocampus, cerebral cortex, and the cerebellum (Chen et al., 2001). Hemizygous 
Mecp2-/+ female mice show no initially significant phenotype. Unlike MeCP2 deficient 
male mice, they show a later onset of symptoms. Between 3 to 9 months of age, one-
half of the Mecp2-/+ mice develop obvious symptoms, including hind limb clasping, 









1.1.5. Breathing phenotype in Mecp2-/y mice 
In vivo investigations by whole body plethysmography demonstrate that at birth 
almost all MeCP2-deficient mice show normal breathing until 28 days of age. 
Henceforward, more and more individuals develop an arrhythmic breathing pattern 
with increased variability in the duration of the respiratory cycle. Between one and 
two months of age, almost all Mecp2-/y mice as well as elder hemizygous Mecp2-/+ 
female mice (> 3 months of age) display an unambiguous disturbed erratic breathing 
phenotype with characteristically frequent apneas lasting one to two seconds (Guy et 
al., 2001; Viemari et al., 2005; Abdala et al., 2010). In situ studies of phrenic and 
vagal motor nerve activity patterns revealed that this is caused by a prolonged post-
inspiratory phase (Stettner et al., 2007). Similar to human RTT patients, apnea is 
often accompanied by preceding hyperventilation cycles, but is not a result of 
impaired sensing of peripheral oxygen chemoreceptors (Bissonnette and Knopp, 
2008). After onset, these breathing disturbances worsen, and it is assumed that the 
mice eventually die from respiratory arrest, usually around P56. Before attempting to 
analyze the progression of breathing dysrhythmias in RTT, it is essential to consider 
how respiratory rhythm and ventilation seem to be controlled in the healthy 
mammalian respiratory network.  
 
1.2. The ponto-medullary respiratory network  
Airflow into and out of the lungs is a fundamental process that provides the organism 
with oxygen and removes carbon dioxide from the blood. Effective ventilation in 
mammals is normally supported through a respiratory rhythm consisting of three 
sequential temporal phases: inspiration (I), post-inspiration (post-I), and expiration 
(E) (Richter, 1982; Ramirez & Richter, 1996).  
The constitutive 3-phase rhythm originates from the functional interactions between 
six different classes of bulbar respiratory neurons, each distinguished according to 


















Figure 1.2. Schema of a simplified oscillator model of the respiratory network.  
The neuronal respiratory rhythm is divided into inspiration (I), post-inspiration (post-I), and expiration 
(E). According to this oscillator model, the three-phase rhythm is generated by six distinct classes of 
respiratory neurons. Pre-inspiratory (pre-I), early-inspiratory (early-I), ramp-inspiratory (ramp-I) and 
late inspiratory (late-I) neurons regulate the I-phase. Ramp-I neurons trigger discharges in phrenic and 
inspiratory intercostal motoneurons. Post-I and late-I neurons are involved in inspiratory phase 
termination. Early-I neurons delay the onset of post-I and late-I neuron discharges. E-neurons fire 
during active expiration, and pre-I neurons are thought to contribute to phase transition from 
inspiration to expiration. In this network model, reciprocal GABAergic and glycinergic inhibition 
between the respiratory neurons plays a pivotal role in cycling between the three phases. The six 
types of neurons receive tonic excitatory synaptic drive from glutaminergic neurons of the reticular 
activating system (RAS) and brainstem chemoreceptor network. 
 
The network depicted here is mainly located within the ventral respiratory group 
(VRG), a bilaterally distributed column in the ventral region of the medulla (fig. 1.3). 
In addition to the VRG neurons depicted here, others with similar rhythmic respiratory 
properties are found in the nucleus of the solitary tract (NTS) on the dorsal region of 
the medulla, and in the nucleus Kolliker-Fuse (K-F) and medial parabrachial region 
(MPBR) of the pons. The NTS is a primary receiving area for pulmonary sensory 
afferents, and along with K-F and MPBR neurons, plays a role in lung inflation-
dependent depression of inspiration and in other aspects of ventilatory control 
(Rybek et al., 2004). Within the VRG resides the pre-Bötzinger complex (pre-BötC), 
which appears to be of particular importance for modulation of the respiratory rhythm. 
It contains five of the six major classes of respiratory neurons that are thought to be 
crucial for rhythm generation (Smith et al., 1991; Connelly et al., 1992). Bilateral 
lessoning of the pre-BötC abolishes the respiratory rhythm (Ramirez et al., 1998). In 
addition, other regions of the VRG also contain neurons with identical discharge 
properties along with synaptic connections that establish them as being important for 
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respiratory rhythm control (Ezure, 1990). In line to their synaptic projections, 
membrane potential oscillations and firing patterns, 4 classes of VRG neurons have 
been identified as being active during inspiration. Ramp-I neurons exhibit a slow 
rising, ramp-like discharge pattern. Many of them are bulbospinal and have excitatory 
synaptic connections with phrenic and intercostal inspiratory motoneurons, while 
others project to vagal pulmonary motoneurons. They give rise to the discharge 
patterns and timing that regulate contractions of the chest wall, diaphragm, and 
control the patency of the tracheobronchial airways. Late-I and post-I neurons have 
inhibitory synaptic inputs to ramp-I neurons that lead to termination of the inspiratory 
phase. Early-I neurons have reciprocal inhibitory connections with post-I and late-I 
neurons. When early-I discharge is terminated by intrinsic membrane conductances, 
post-I and late-I neurons are released from inhibition and fire to terminate inspiration. 
Late-E (E2) neurons of the caudal VRG discharge to promote active contraction of 
the expiratory intercostal muscles and abdomen. They are not essential for 
constitutive breathing since expiration for the most part is passive. Pre-I neurons 
discharge in parallel with cessation of E2 neurons, hence they are thought to 
contribute to phase transition from expiration to inspiration.  
 
1.3. Neurochemical control of respiratory rhythm in the VRG 
The six classes of VRG neurons receive tonic excitatory glutamatergic input from 
neurons of the brainstem reticular activating system (RAS) and brainstem 
chemoreceptor network, resulting in activation of postsynaptic AMPA and NMDA 
receptors. In addition, VRG neurons interact antagonistically through glycinergic and 
GABAergic inhibitory synaptic connections (Ezure et al., 1990; Merril et al., 1983; 
Bianchi et al., 1995; Schmid et al., 1996). Simultaneous blockade of glycine and 
GABA receptors within the pre-BötC with strychnine and bicuculline leads to loss of 
rhythmic breathing in in vivo and in vitro (Pierrefiche et al., 1998; Paton et al., 1994; 
Paton & Richter, 1995) and disrupts respiratory rhythmic neuron discharges in in vitro 
experiments (Ramirez et al., 1996). 
Respiratory network rhythm and pattern is also modulated by an assortment of 
synaptically released neurochemicals such as ATP, neurokinins, histamine, 
















Figure 1.3. Schema of the localization of regions important for respiratory rhythm generation. 
The schematic representation shows a sagittal (left) and a transversal section (right) from a mouse 
brainstem. The breathing center, which hosts the respiratory network (colored) is column-like 
bilaterally arranged. The pre-Bötzinger complex (pre-BötC, red) is of special importance for the 
respiratory rhythm generation. The principal nucleus of the inferior olive (IOPr) is shown as an 
anatomical landmark for the pre-BötC. Abbreviations: thalamic reticular nucleus (RTN), compact part 
of the nucleus ambiguus (cNA), Bötzinger complex (BötC), nucleus tractus solitarii (NTS), ventral 




The biogenic monoamine serotonin (5-hydroxytryptamine; 5-HT) was originally 
isolated from the blood serum and found to increase constrictor tone in a variety of 
blood vessels (Rapport et al., 1948). It is synthesized in a two-step mechanism from 
the precursor amino acid L-tryptophan (5-HTP), catalyzed by the rate-limiting enzyme 
tryptophan hydroxylase (TPH) and by amino acid decarboxylase (DDC). After release 
and binding to its receptors, serotonin is removed from the synaptic cleft by re-uptake 
through the serotonin transporter SERT. Intracellular serotonin can either be restored 
in vesicles by vesicular monoamine transporter (VMAT2) or be degraded to 5-
hydroxyindolacetic acid (5-HIAA) by monoamine oxidase A (MAO-A) (Hilaire et al., 
2010). 
Although roughly 95% of serotonin is built and located in enterochromaffin cells in the 
gastrointestinal tract regulating intestinal mobility, which is important for the energy 
balance (Tecot, 2007), 5-HT and its receptors are present in all organs and tissues, 
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including the brain (Berger et al., 2009). Serotonin is involved in almost al basic 
physiological functions and behaviors, such as eating, cognition, sleep, stress, 
aggression, circadian rhythmicity, neuroendocrine functions, and breathing (Ciarleglio 
et al., 2011; Dinan, 1996; Geldenhuys et al., 2011; España & Scammell, 2011; Bailer 
& Kaye, 2011; Magalhães et al., 2010). Moreover, due to its influence on cell division, 
neuronal maturation, and axonal outgrowth, serotonin is also involved in 
developmental processes (Sodhi & Sanders-Bush, 2004). 
 
1.4.1. Serotonin in the brain  
The presence of serotonin in the mammalian brain was first described in the 1950s 
(Twarog & Page, 1953). It is mainly located and produced by cell bodies, which are 
located in the previous defined raphé nuclei. The raphé nuclei represents nine 
discrete cell clusters (B1 - B9) within the pons and the upper medulla lying to either 
side of the midline (Dahlström & Fuxe, 1964; Steinbusch, 1981). Each nucleus 
projects to different regions within the CNS (fig. 1.4). Nuclei, which are more rostrally 
and dorsally located (B6 - B9), innervate via the median forebrain bundle many parts 
of the cortex, hippocampus, limbic system, and hypothalamus, whereas fibers from 
nuclei that are located caudally (B1 - B4) mainly project to the gray matter of the 
spinal cord and the brainstem (Hornung, 2003; Törk, 1990; Jacobs & Azmita, 1992). 
Due to the strong innervation and the ubiquitous expression of serotonin receptors in 
almost all cytoarchitectonic regions of the brain it is not surprising that an impaired 
serotonergic system is associated with several neurological aliments, such as 
obsessive-compulsive disorder, anxiety, disorders of energy balance, autism, 














Figure 1.4. Schema of the anatomical localization of the rodent serotonergic system. 
The cell bodies of serotonergic neurons are located in distinct nuclei (B1 - B9) innervating almost all 
regions of the brain. The more dorsal and medullary located nuclei (B1 - B4, red) project to various 
regions in the brainstem including the respiratory system. Abbreviations: hippocampus (Hip), third 
ventricle (3V), caudal (c), ventral (c). 
 
1.4.2. Expression and function of serotonin receptors in the respiratory 
network 
The pivotal role of the serotonergic system for stable breathing has been shown in 
many studies over the past three decades (Fallert et al., 1979; Monteau & Hillaire, 
1991; Hilaire et al., 1993; Lindsay & Feldman, 1993; Morin et al., 1991; Lalley, 1986; 
Lalley et al., 1995; Bou-Flores et al., 2000; Pena & Ramirez, 2002; Richter et al., 
2003; Ladewig et al., 2004; Ptak et al., 2009).  
Hence, it is not surprising that the disturbed breathing pattern of diverse neurological 
disorders including Prader Willi syndrome (PWS), Joubert syndrome (JS), sleep 
apnea syndrome (SAS), congenital central hypoventilation syndrome (CCHS), and 
sudden infant death syndrome (SIDS) have attributed to impaired serotonergic 
transmission (Ren et al., 2003; Pagliardini et al., 2005; Gaultier & Gallego, 2008; 
Saito et al., 1999; Waters, 2010; Weese-Mayer et al., 2008; Paterson et al., 2009).  
The brainstem respiratory network is densely innervated by predominantly 
descending fibers from serotonergic neurons of the caudal raphé nuclei (Connelly et 
al., 1989; Holtman, 1988). These neurons are tonically active and exhibit ongoing 
discharges to release continuously serotonin, which presumably influences breathing 
and respiratory responses to hypoxia (Richter et al., 1999; Depuy et al., 2011). 
The importance of the serotonergic system to the rhythmic activity is further 
supported by abundant 5-HT receptor expression in the respiratory network (Richter 
et al., 2003; Hilaire et al., 2010).  
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According to the International Union of Basic and Clinical Pharmacology (IUPHAR) 
serotonin receptors are divided into seven sub-families (Hoyer et al., 1994). 
With the exception of 5-HT3A-C receptors, which are ligand-gated ion channels, 5-HT 
receptors belong to a large group of G-protein-coupled receptors (GPCRs) (fig. 1.5). 
It is known that thirteen of the approximately 1,000 identified genes that the 
mammalian genome codes for GPCRs (O’Callaghan et al., 2012; Fredriksson et al., 
2003) are selectively activated by serotonin (Hoyer et al., 2002) (fig. 1.5). Alternative 
splicing of the C-terminus of 5-HT4 and 5-HT7 receptors as well as alternative RNA 
editing of 5-HT2C receptors additionally increase the number of serotonin receptor 


















Figure 1.5. Phylogenetic tree of the serotonin receptor (5-HTR) family and their signaling 
properties. 
Except for the 5-HT3 subclass, which represents a ligand-gated Na+/K+ ion channel, all 5-HT receptors 
belong to the superfamiliy of Rhodopsin-like G-protein coupled receptors (class A). 5-HTR2 subclass 
activates phospholipase C (PLC) by the G-protein Gq/11, which cleaves phosphatidylinositol 4,5-
bisphosphate (PIP2) in inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which in turn results 
in an increase of intracellular Ca2+ and activation of protein kinase C (PKC). The remaining 5-HTRs 
either increase or decrease the intracellular cAMP level by activation or inhibition of the adenylyl 
cyclase C (AC) mediated by the inhibitory (Gi) or stimulatory G-protein (Gs) pathway. Increased cAMP 
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concentrations activate the protein kinase A (PKA). The putative G-protein of 5-HTR5 are currently 
unknown, but are expected to bind to Gi due to sequence homology to 5-HTR1A. 
 
As is typical for metabotropic GPCRs, serotonin receptors are integral membrane 
proteins comprising seven hydrophobic transmembrane domains connected by three 
intracellular loops (termed I1 - I3) and three extracellular loops (termed E1 - E3). 
Furthermore, serotonin receptors possess an extracellular N-terminus and an 
intracellular C-terminus, where they couple to their corresponding heterotrimeric G-
protein.  
Depending on the class of the alpha subunit of the heterotrimeric G-protein 
associated with the serotonin receptor, they switch on different signaling pathways.  
Activation of the 5-HT2 receptor class turns on the Gαq/11 mediated signaling pathway, 
which results in the activation of phospholipase C (PLC), leading to elevation of 
second messengers diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) and, 
subsequently, to an increase of the cytoplasmic Ca2+ concentration. 5-HT4, 5-HT6, 
and 5-HT7 receptors couple preferably to stimulatory G-proteins (Gαs) leading to 
activation of the AC and consequently to intracellular cAMP elevation. 
The 5-HTR1 class comprises 5 subtypes (A - F; currently there is no 5-HTR1C 
defined), which couple preferably to inhibitory G-proteins (Gαi/Gαo) to inhibit adenylyl 
cyclase avoiding cAMP formation (Bockaert et al., 2006).  
The two members of the 5-HT5 subclass are distinguishable from other serotonin 
receptor classes, but less characterized in their physiological response (Hoyer et al., 
2008). In rodents they share an unusual high homology (> 75%), but they exhibit only 
a low amino acid sequence homology (< 50%) to other serotonin receptors especially 
in their transmembrane regions (Noda et al., 2004; Hoyer et al., 2002). 5-HTR5A has 
been shown to couple also to Gαi/Gαo, whereas the corresponding G-protein for the 
5-HTR5B is still unknown (Francken et al., 1998; Hannon & Hoyer 2008).  
The expression of several 5-HT receptors within the respiratory network and their 
relevance for stable breathing has been described over the past two decades 
(Richter et al., 2003). For example, activation of the 5-HTR1A is known to overcome 
apneustic breathing caused by pharmacological treatment or disturbances within the 
brainstem respiratory network (Garner et al., 1989; Lalley et al., 1994; Wilken et al., 
1997; El-Khatib & Jamaleddine, 2003). The augmentation of 5-HTR1A-mediated 
inhibitory glycinergic inward Cl- currents in predominantly early-I neurons results in 
disinhibition of antagonistically connected post-I-neurons, which leads to termination 
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of the inspiratory phase (Manzke et al., 2009; Manzke et al., 2010). Moreover, 
pharmacological activation of 5-HT4 receptors reverses opioid induced breathing 
depression without loss of analgesia (Manzke et al., 2003), and pre-synaptically 
located 5-HT1B receptors modulate the central excitatory synaptic drive to phrenic 
motoneurons (Di Pasquale et al., 1997). The 5-HTR2A, which is abundantly 
expressed in neurons of the pre-BötC, stimulates breathing and helps to maintain 
gasping during hypoxia or ischemia (Lalley et al., 1995; Pena & Ramirez, 2002; 
Niebert et al., 2011; Tryba et al., 2006; Toppin et al., 2007). The 5-HTR2A seems to 
be constantly activated by serotonin, since receptor blockade decreases the 
frequency of the phrenic nerve discharges in in situ (Niebert et al., 2011). An 
activating effect on phrenic nerve discharge pattern has also been reported for 5-
HTR2B (Niebert et al., 2011) and 5-HTR2C.  
The modulation effects through serotonin receptors targets predominantly glycinergic 
inhibitory interneurons affecting inhibition of antagonistically connected respiratory 
neurons, but is also important for synchronization of synergistic neurons (Lalley et al., 
1994; Lalley et al., 1995; Manzke et al., 2009; Manzke et al., 2010) 
Systemic administration of selective 5-HTR7 agonists reduces respiratory frequency 
in rats studied in in situ experiments (Manzke et al., 2009). As the receptor is 
important for developmental brain plasticity, it may play a role in the maturation and 






1.4.3. Serotonergic system in RTT 
Serotonergic effects on breathing disturbances were originally attributed to direct 
modulation of the respiratory rhythm (Nomura et al., 1987; Segawa, 2001; Kerr & 
Julu, 1999) or to effects on neurodevelopmental processes such as cell division, 
neuronal migration, cell differentiation, and synaptogenesis (Lauder, 1993; Azmitia 
2001; Vitalis & Parnavelas, 2003).  
Although in Mecp2 null mice the serotonergic transmission is deregulated no 
alterations in the raphé nuclei and its ascendant serotonergic fibers are observed at 
P21 and P56 (Santos et al., 2010). Some groups reported reduced levels of 
serotonin in different brain regions and in the cerebrospinal fluid in both human 
patients as well as in MeCP2 deficient mice (Zoghbi et al., 1989; Paterson et al., 
2005; Viemari et al., 2005). Additionally, some patients show abnormalities in the 
serotonin transporter (SERT). 
However, until now there is no information about specific genes involved in the 
serotonergic transmission, which may be altered in regions of the respiratory network 
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2. Aim of this work 
 
As the foundation for this dissertation study, the hypothesis was established that 
impaired serotonergic transmission and/or failure of glycinergic inhibition contributes 
to breathing disturbances in RTT patients. Accordingly, a major goal of this thesis is 
to investigate gene expression of specific serotonin receptors and transporters as 
well as glycine receptor subunits and transporters within the VRG in a mouse model 
for RTT that has a knockout in the Mecp2 gene encoding for the transcription factor 
MeCP2. Positive findings will hopefully lead to a detailed examination of potential 
candidates in terms of their gene regulation, signaling pathway, and their pathological 
effects on breathing.  
 
As serotonin receptors are forceful targets for pharmacological treatment, this study 
may contribute to find new strategies to treat life-threatening breathing disturbances 
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3. Materials and Methods 
 
3.1. Materials 
Materials used in this thesis are listed in the following tables. Unless otherwise 




Systec 5075 ELV Systec GmbH (Wettenberg) 
Blotting-Apparatus 
iBlot Invitrogen (Karlsruhe) 
Cell-counting chamber 
Neubauer cell chamber Labor Optic (Friedrichsdorf)  
Countess® Invitrogen 
Centrifuges 
5415R Eppendorf (Hamburg) 
Centrifuge 5415D Eppendorf 
Mikro 200R Hettich (Tuttlingen) 
Documentation 
AlphaImager EC (western blot) Alpha Innotec Corporation (San Leandro, 
USA) 




Horizontal, self-made (agarose gel) by workshop UMG (Göttingen) 
Vertical, XCell SureLock  Invitrogen 
Freezers 
Comfort (-20°C) Liebherr (Biberach) 
U535 Innova (-80°C) New Brunswick Scientific (Edison, USA) 
Heat blocks 
Thermofixer comfort Eppendorf 
Thermostat 5320 Eppendorf 
Incubators 
Incucell IUL Instruments (Königswinter) 
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Sanyo CO2-Inkubator MCO 18AIC MS Laborgeräte (Wiesloch) 
Unimax2010 Heidolph (Schwabach) 
Luminometer 
Infinite M200 PRO Tecan (Crailsheim) 
Microtoms 
CM1510S Leica Microsystems (Bensheim) 
Frigomobil Reichert-Jung (Seefeld) 
Hm 400 Microm (Walldorf) 
Ultramikrotom Leica 
Microscopes 
EM 900 Zeis (Göttingen) 
Meta-LSM 510 Zeiss 
Peristaltic pump 
Pump 101U Watson and Marlow (Rommerskirchen) 
pH meter 
inoLab pH 720 WTW (Weilheim) 
Pipettes 
2.5-, 10-, 20-, 100-, 200, 1000-µl Eppendorf 
10-, 20-, 100-, 200, 1000-µl Gilson (Limburg-Offheim) 
300-µl multichannel  Eppendorf 
accu-jet BRAND GmbH & CoKG (Wertheim) 
Macro pipette controller BRAND GmbH & CoKG,  
Multipipette plus Eppendorf 
Photometer 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific (Dreieich) 
Power supplies 
EV-231 Biotec-Fischer (Reiskirchen) 
Power-Pac 3000 BIO-RAD (München) 
Shakers / wheeled walker 
Duomax 1030 Heidolph Instruments  
Roller Shaker "Assistent" RM5 Glaswarenfabrik Hecht (Sondheim) 
Rotamax 120 Heidolph Instruments 
Titramax 1000 Heidolph Instruments 
Genius 3 IKA (Staufen) 
MATERIALS AND METHODS 
 21 
Sterile bench 
HeraSafe HSP Heraeus (Berlin)  
Scales 
572 Kern & Sohn (Balingen-Frommern) 
Alt 100-5AM Kern & Sohn 
Thermocyclers 
Labcylers SensoQues (Göttingen) 




HD2070 MS72 BANDELIN electronic (Berlin 
Water bath 
Ultrasonic cleaner VWR International (Darmstadt) 
 
 
3.1.2. Consumables  
Aluminum foil  Roth (Karlsruhe) 
Cell culture plates 






(1-, 5-, 10-ml) 
Eppendorf (Hamburg) 
Coverslips (24 x 50 mm) Roth (Karlsruhe) 
Glasware Duran Group (Mainz) 
Microtiter plates (96-well) Nunc 
Microscope slides (Superfrost® Plus) Thermo Fisher Scientific (Dreieich) 
Nitrile gloves Top glove (Duisburg) 
Parafilm Pechiney (Chicago, USA) 
PCR plates (96-well) BIO-RAD (Müchen) 
Pipette tips  
(10-, 100-, 200-, 1000-µl) 
nerbe plus (Winsen/Luhe) 
Reaction tubes 
(0.2-, 0.5-, 1.5-, 2-ml) 
nerbe plus 
Surgery B. Braun (Melsungen) 
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(cannula, scalpels, syringes) 
Serological pipettes 
(5-, 10-, 25-, 50-ml) 









1,4-Dithiothreitol DDT AppliChem (Darmstadt) 
Acetic acid (100%)  Roth (Karlsruhe) 
Acetone  Roth 
Agarose (for electrophoresis)  Peqlab (Erlangen) 
ß-Mercaptoethanol β-ME Merck (Darmstadt) 
BSA fraction V  Roth 
Calcium chloride CaCl2 Roth 
Chloroform  Roth 




 Invitrogen (Karlsruhe) 
Dimethyl sulfoxide DMSO Sigma-Aldrich (Taufkirchen) 
ECL Western Blot kit  Amersham, GE Healthcare 
(München) 
Ethanol, absolute ultra pure EtOH Roth 
Ethanol, denatured (99%)  CVH (Hannover) 
Ethidium bromide  Merck 
Ethylenediaminetetraacetic acid EDTA Roth 
Ficoll 70  Sigma-Aldrich 
GeneRuler® 1 kb-DNA-Ladder  Fermentas (St. Leon-Rot) 
GeneRuler® 100 bp-DNA-Ladder  Fermentas 
Glucose  Roth 
Glycerol  Sigma-Aldrich 
Glycine  Roth 
GlycoBlue  Ambion 
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Hydrochloric acid (32%) HCl Roth 
IGEPAL CA-630  Sigma-Aldrich 
Immersion oil  Zeiss (Göttingen) 
Isopropanol (ultra pure)  Roth 
LB Agar  Roth 
LB Broth  Roth 
Lipofectamine2000  Invitrogen  
Lithium chloride LiCl Roth 
Magnesium chloride MgCl2 Roth 
Magnesium sulfate MgSO4  Roth 
Methanol MeOH Roth 
Nuclease-Free Water  Ambion 
Paraformaldehyde  PFA Roth 
Ponceau S  Sigma 
Potassium chloride KCl Roth 
Potassium dihydrogen phosphate KH2PO4 Roth 
Precision Plus Protein™ 
Kaleidoscope™ protein standard 
 BIO-RAD 
Protease inhibitor cocktail  Fermentas 
Roti phenol  Roth 
Saccharose  Roth 
Salmon Sperm DNA/Protein A 
Agarose 
 Millipore (Eschborn) 
Sodium acetate NaAc Roth 
Sodium azide NaN3 Roth 
Sodium chloride NaCl Roth 
Sodium deoxycholate  Roth 
Sodium dodecyl sulfate  SDS Roth 
Sodium hydrogen carbonate NaHCO3 Roth 
Sodium hydrogen phosphate Na2HPO4 Roth 
Sodium hydroxide NaOH Roth 
Tris  Roth 
Triton X-100  Sigma-Aldrich 
Trizol  Invitrogen 
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Tween® 20  Sigma-Aldrich 
 
 
3.1.4. Kits and ready-to-use material 
Name  Company Application 
DC Protein Assay BIO-RAD 
(München) 
Protein determination 
DirectX Direct Cyclic AMP ARBOR ASSAYS 
(Michigan, USA) 
cAMP measurements 
Dual-Luciferase® Reporter Assay Promega 
(Mannheim) 
Promoter assay 
HISpeed Plasmid Maxi Qiagen (Hilden) Plasmid preparation  





iScript cDNA Synthesis  BIO-RAD cDNA synthesis 
Novex 4 - 20% Tris Glycine Gel Invitrogen SDS page 
OIAprep Spin Qiagen  Plasmid preparation  
QIAquick Gel Extraction Qiagen DNA purification 




Name (conc.) Company Application (final conc.) 
Alkaline phosphatase  
(1 u/µl) 
Fermentas (St. Leon-Rot) Cloning (1: 30) 
Benzonase (250 u/µl) Sigma-Aldrich (Taufkirchen) Protein extraction (1: 1,000) 
BmtI (10 u/µl) NEB DNA restriction (1 : 30) 
DNase (10 u/ml) Fermentas RNA extraction (1 : 50) 
EcoRI (10 u/µl) NEB DNA restriction (1 : 30) 
Fast SYBR® Green (2x) Applied Biosystems  q-PCR (1x) 
Proteinase K  
(16.4 mg/ml) 
Fermentas ChIP (1 : 100) 
RNase (10 mg/ml) Fermentas ChIP (1 : 1,000) 
T4 DNA Ligase (1 u/µl) Fermentas Cloning (1: 20) 
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Name Insert  Application 
pcDNA3.1(-) - Eukaryotic overexpression 
pEGFP-Endo Fusion construct of eGFP and 
Rab7 (Choudhury et al., 2002) 
Eukaryotic overexpression 
(marker for endosomes) 
pEYFP-ER Fusion construct of eYFP and 
targeting sequence of calreticulin 
(Fliegel et al.,1989) 
Eukaryotic overexpression 
(marker for endoplasmic 
reticulum) 
pEYFP-Lyso  Fusion construct of eYFP and 
Lamp1 (Sherer et al., 2003) 
Eukaryotic overexpression 
(marker for lysosome) 
pEYFP-Mem Fusion construct of EYFP and N-
terminal 20 amino acids of 
neuromodulin (Skene & Viràg, 
1989) 
Eukaryotic overexpression 
(marker for cell membrane) 
pEYFP-Mito Fusion construct of eYFP and the 
mitochondrial targeting sequence 
from of human cytochrome c 
oxidase (Rizzuto et al., 1989) 
Eukaryotic overexpression 
(marker for mitochondria) 
pGL4 Htr5 promoter Promoter assay 
pTarget Mecp2 Eukaryotic overexpression 
pTarget Fusion construct of GFP and Gαi3   
pTarget Fusion construct of GFP and Gαs   
 
 
3.1.7. Primers for q-PCR 
Gene Accession number Sequence (5’  3’) 
Forward 
Reverse 
Glra1 NM_020492.3 CATTGTATTCTTCAGCCTTGC 
	   	   ACAAGTCAGGCTTCCAGATG 
Glra2 NM_183427.4 CAAACCACTTCAGGGAAGC 
	   	   CAAATCCAGGGAATCATCTG 
Glra3 NM_080438.2 GGATCCCGGGCCTCCTTACC 
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   TCCCTCACCTCATCATCCGTGTC 
Glra4 NM_010297.2 TGTTCTCTACAGCATCAGATTG 
	   	   CAGGATGACGATGAGTAGGC 
Glrb NM_010298.5 GTACTTGTGCCCATCTCAGC 
	   	   GTCAGTGCATCTGAGCCTCT 
Gphn NM_145965.2 CCAAGATCCTTCTTTGTTGGGTGGG 
	   	   AGAGAGCATGCCCAGAGGTGTG 
Slc6a9 NM_145965.2 AGTCAAGTCTTCAGGGAAAGTG 
	   	   TTGGTGATACTGATAATGACGC 
Slc6a5 NM_148931.3 CACCACTACCATACCGGAG 
	   	   TCCACACAGACACAGGACC 
Atf7 NM_146065.1 TGCCCAGCCACAGGTCTCTC 
	   	   AGGCTGCAGCTCTGTTTCGC 
Mapk14 NM_011951.3 GGAGGAATTCAATGACGTGTACCTGG 
	   	   CATCAGTGTGCCGAGCCAGC 
Gapdh NM_008084.1 CAAGCTCATTTCCTGGTATGAC 
	   	   AGGCCCCTCCTGTTATTATG 
Hprt NM_013556.2 ATTAGCGATGATGAACCAGG 
	   	   GTCAGCAAAGAACTTATAGCCC 
Htr1a NM_008308.4 AACTATCTCATCGGCTCCTT 
	   	   GATTGCCCAGTACCTGTCTA 
Htr1b NM_010482.1 CTCCATCTCTATTTCGTTGC 
	   	   GTCTTGTTGGGTGTCTGTTT 
Htr1d NM_008309.4 CCATCCATCTTGCTCATTAT 
	   	   CACCTGGTTGAAAAAGAGAG 
Htr1f NM_008310.3 TTTCTACATCCCGCTTGTAT 
	   	   TCGGACAAGGATTTTTCTAA 
Htr2a NM_172812.2 TGTGATGCTTTTAACATTGC 
	   	   CCAACTTACTCCCATGCTAC 
Htr2b NM_008311.2 GAACATCCTTGTGATTCTGG 
	   	   AGGCAGTTGAAAAGAGAACA 
Htr2c NM_008312.4 CTATTTTCAACTGCGTCCAT 
	   	   ATTCACGAACACTTTGCTTT 
Htr3a NM_013561.2 TGGTCCTAGACAGAATAGCC 
	   	   GGTCTTCTCCAAGTCCTGA 
Htr4 NM_008313.4 CCTCACAGCAACTTCTCCTT 
	   	   TCCCCTGACTTCCTCAAATA 
Htr5a NM_008314.2 TGCTCTTTGTGTACTGGAAA 
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   ACGTATCCCCTTCTGTCTG 
Htr5b NM_010483.3 GGAGTCTGAGATGGTGTTCA 
	   	   AATATCCAAGCCACAGGAAT 
Htr6 NM_021358.2 CTGAGCATGTTCTTTGTCAC 
	   	   CATGAAGAGGGGATAGATGA 
Htr7 NM_008315.2 GTTAGTGTCACGGACCTCAT 
	   	   ATCATTTTGGCCATACATTT 
Slc6a4 NM_010484.2 AAGCCAAGCTGATGATGTAA 
	   	   TCCTCACATATCCCAGTCAG 
Tph2 NM_173391.3 CAGGGTCGAGTACACAGAAG 
	   	   CTTTCAGAAACATGGAGACG 
Ddc NM_001190448.1 GCAGTGCCTTTATCTGTCCT 
	   	   GAATCCTGAGTCCTGGTGAC 
Mecp2 NM_010788.3 TCCTTGGACCCTAATGATTT 
	   	   TTTCACCTGAACACCTTCTG 
 
 





Sequence (5' --> 3') 
Forward 
Reverse 
Htr5b WT (Genotyping) CTCTGCAGTCGGTTTGATG 
 
GTAGAGTCACCACAAGCAC 
Htr5b KO (Genotyping) GCAGCGCATCGCCTTCTATC 
 
GTGCTGGGATTAGAAGTCC 
Mecp2 WT (Genotyping) GACCCCTTGGGACTGAAGTT 
 
CCACCCTCCAGTTTGGTTTA 
Mecp2 KO (Genotyping) CCATGCGATAAGCTTGATGA 
 
CCACCCTCCAGTTTGGTTTA 
T7 (pcDNA3.1(-); Insert sequencing) TAATACGACTCACTATAGGG 
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3.1.9. Primers for cloning 
Gene (CDS) Sequence (5’   3’) Restriction side 












































3.1.10. Primary antibodies  
Antibody (species) Company Application (final conc.) 
Anti-5-HTR5B (rabbit) Abcam (ab101907) IHC (1 µg/ml) 
Anti-5-HTR5B (rabbit) Homemade IHC (1 µg/ml) 
WB (2 µg/ml) 
Anti-GAPDH (mouse) Biotrend (6C5) WB 0.2 µg/ml) 
Anti-MeCP2 (rabbit) Cell Signaling (D4F3) ChIP (0.5 µg/ml) 
WB (1 µg/ml) 
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3.1.11. Secondary antibodies  
Antibody Conjugate Company Application 
goat anti-rabbit IgG Atto 488 Sigma-Aldrich 
(Taufkirchen) 
IHC 
goat anti-rabbit IgG Chromeo 546 Active Motif (Carlsbad, 
USA) 
IHC 
goat anti-rabbit IgG Atto 647 Sigma-Aldrich IHC 
goat anti-mouse IgG Chromeo 546 Active Motif IHC 
goat anti-mouse IgG Atto 488 Sigma-Aldrich IHC 
goat anit-mouse IgG HRP DAKO (Hamburg) WB 
goat anti-rabbit IgG HRP DAKO (Hamburg) WB 
rabbit mAb IgG - Cell Signaling (DA1E) Isotyp control; 
ChiP 
    
 
3.1.12. Pharmacological substances 
Name  Company Application (final conc.) 
8-OH-DPAT Tocris WHBP (0.2 - 0.4 µM) 
Ampicillin  Sigma Bacterial culture (50 µg/ml) 
Ethidium bromide  Merck Nucleic acid visualization (0.25 
µg/ml) 
Forene (isofluran) Company Animal preparation 
Forskolin Tocris cAMP (1 µM) 
WHBP (1 µM ) 
Norcuronium bromide Tocris WHBP (2.5 ng/ml) 
Rp-cAmps Tocris WHBP (0.2 - 0.4 µM) 
Serotonin  Sigma-Aldrich 
(Taufkirchen) 
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3.1.13. Media and supplements for cell culture 
 
 
3.1.14. Cell line 
Name Origin Source 
N1E-115 (mouse) Neuroblastoma tumor Amano et al., 1972 
 
 
3.1.15. Mouse lines 
Name Genotype Background Source 
C57BL/6J wt  Jackson Laboratory 
129P2(C)-Mecp2tm1-1Bird Mecp2-/y C57BL/6J Guy et al., 2001  
129SvEvBrd Htr5b-/- C57BL/6J Taconic (Denmark) 
TgN-(hGFAP-EGFP)  C57BL/6J  
 
 
3.1.16. Computer software 
Program / Internet 
side 




FinchTV Geospiza (USA) Sequence analysis 
LabChart ADInstruments (Spechbach) Data analysis 
LSM Image Browser Zeiss (Göttingen) Image processing 
Magellan Tecan (Männedorf) Data analysis 
Reagent  Company Application (Dilution) 
Dulbecco’s Modified Eagle’s 




Dulbecco’s PBS Gibco Washing 
Fetal calf serum (FCS, heat 
inactivated) 
Gibco cell culture (1 : 10)   
Optimem Gibco Transfection, approach 
Penicillin (10,000 U/ml) / 
streptomycin (10 mg/ml) mix 
Gibco cell culture (1 : 100) 
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NCBI http://www.ncbi.nlm.nih.gov/ Basical information 
Office Excel Microsoft (Unterschleißheim) Data analysis 
Office Word Microsoft Writing 




Prism GraphPad (La Jolla, USA) Data analysis 
SerialCloner SerialBasics (Internet, free) Sequence comparison 





3.1.17. Universal washing buffers 
Buffers were prepared with double distilled water (ddH2O) of a deionization facility 
(Millipore) and afterwards autoclaved for 20 min at 121°C and 1.1 bar. X-fold stock 
















10 mM Tris 
1 mM EDTA 
pH 8.0 
 
10x PBS  
1.5 M NaCl 
38 mM NaH2PO4 




100 mM Tris 




10 % 10x TBS 
0.05 % Tween20 
pH 7.6 
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3.2. Methods 
The experimental procedures were performed in accordance with European 
Community and National Institutes of Health guidelines for the Care and Use of 
Laboratory Animals. The Ethics Committee of the Georg-August-University, 
Göttingen, Germany approved the study. 
 
3.2.1. Animal work 
This section describes origin, generation, and handling of all mouse models used in 
this study at all conducted approaches.  
 
3.2.1.1. Animal models 
The Mecp2 knockout mouse (Mecp2-/y), which is a model for Rett syndrome, strain 
B6.129P2(C)-Mecp2tm1-1Bird (Guy et al., 2001) maintained on a C57BL/6J 
background was obtained from The Jackson Laboratory (Bar Harbor, ME, USA). 
Mecp2 knockout males (Mecp2-/y) were generated by crossing hemizygous Mecp2+/- 
females with C57BL/6J wild type males. The knockout mouse model for serotonin 
receptor 5B, strain (129SvEvBrd), maintained on a C57BL/6J background was 
obtained from Taconic (Denmark). The Mecp2-/y,Htr5b-/--double-knockout mice were 
obtained by crossbreeding female filial 1 (F1) generation (Mecp2+/-,Htr5b+/-) mice with 
male Mecp2+/y,Htr5b+/- mice. TgN-(hGFAP-EGFP) transgenic mice, which express 
enhanced green fluorescent protein (EGFP) under the control of the human glial 
fibrillary acidic protein (hGFAP) promoter (Nolte et al., 2001), were kindly provided by 




Animals were kept in a temperature- und humidity-controlled 12 h light-dark rhythm 
and had free access to water and standardized pellet food. 
 
3.2.1.3. Genotyping 
The genotype of newborn mice were determined using PCR on DNA isolated from 
mice tail biopsies. For PCR condition and primer sequences for genotype 
identification refer to 3.1.8. 
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3.2.1.4. Preparation of fresh brain tissue for quantitative PCR, western blot, and 
cAMP measurement 
Before decapitation, mice were deeply anesthetized with isofluran until they were 
unresponsive to painful stimulus. After opening the skull the brain was isolated and 
immediately frozen on dry ice. For long-term storage brains were transferred 
to -80°C. 
 
3.2.1.5. Fixation of brain tissue for immunohistochemistry 
Mice were deeply anesthetized with isoflurane until they were unresponsive to painful 
stimulus. Mice were transcardially perfused with 50 ml 0.9% NaCl (10 ml/min) to 
remove the blood followed by 4% PFA/PBS to start brain fixation. After removal from 
the skull, brains were post-fixed for 4 h with 2% PFA/PBS at 4°C. For cryoprotection 
tissue was transferred first to 10% Sucrose/PBS for 2 h and afterwards to 30% 
Sucrose/PBS at 4°C overnight and eventually frozen at -28°C. 
 
3.2.1.6. Human brain tissue for immunohistochemistry 
Paraformaldehyde-fixed (4%) human brainstem tissue of healthy young casualties (1 
- 2 years of age) was obtained from the tissue bank of the Department of Legal 
Medicine, University of Göttingen, and kindly provided by Prof. Michael Klintschar. 
  
3.2.2. Determination of breathing rhythm 
 












1.25 mM MgSO4 
1.25 mM KH2PO4 
5 mM KCl 
125 mM NaCl 
2.5 mM CaCl2 
25 mM NaHCO3 
10 mM glucose 
0.1785 mM Ficoll 70 
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In collaboration with Anna-Maria Bischoff (Department of Neuro- and Sensory 
Physiology, Georg-August University of Göttingen), who did the technical work, the 
output of the neuronal breathing rhythm was measured by recording of the phrenic 
nerve activity (PNA) during the in situ working heart brainstem preparation (WHBP). 
This method was developed by Paton (Paton et al., 1996) and enables 
pharmacological manipulation of the breathing rhythm by application of drugs. 
Furthermore, in contrast to other approaches such as en bloc brainstem preparations 
or acute slice culture the WHBP is suitable for studying of the 3-phase rhythm in 
adult mammals (Richter & Spyer, 2001). 
Mice were deeply anesthetized with isoflurane until they were unresponsive to painful 
pinch into their forepaw. Animals were then decerebrated at the pre-collicular level 
and cerebellectomized, bisected below the diaphragm, and the skin was removed. 
The upper body was placed in a recording chamber and perfused retrogradely at 10 - 
20 ml/min via the thoracic aorta with artificial cerebrospinal fluid (ACSF) aerated with 
carbogen (5% CO2 / 95% O2; pH 7.35). The perfusate was warmed to 30°C as 
measured in the scull base, filtered twice and re-circulated. Norcuronium-bromide 2.5 
ng/ml was added for muscle relaxation. The perfusion pressure was adjusted to 50 to 
65 mmHg. Using a glass suction electrode, phrenic nerve discharges were recorded 
as an index of central respiratory rhythm. Drugs were added to the perfusate for 
specific pharmacological manipulation. 
 
3.2.2.2. Plethysmography 
In collaboration with Prof. Swen Hülsmann (Department of Molecular Neurohysiology 
and Cellular Biophysics, Georg-August University of Göttingen) ventilation was 
measured by whole-body-plethysmography that allows measuring pressure changes, 
resulting from the warming of the inspired air and cooling during expiration 
(Drorbaugh and Fenn, 1955). 
Mice were placed in a custom made Plexiglas chamber (300 ml volume) that was 
connected to a differential low-pressure transducer (DP1 03, Validyne Engineering, 
Northridge, CA). The other channel of the differential pressure transducer was 
connected to a 300 ml reference chamber to make measurement mostly independent 
from other pressure changes (Bartlett & Tenney, 1970). The pressure transducer was 
connected to a sine wave carrier demodulator (CD-15). Pressure fluctuations were 
Band-Pass filtered (1.5 - 500 Hz), amplified (four times) before storing. For 
digitization an ITC-16 interface (InstruTECH/HEKA, Lambrecht) was used controlled 
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by Axograph 4.8 software (Axon Instruments, Foster City, CA) and sampling rated of 
1 kHz. Animals were allowed to freely explore the chamber. To prevent accumulation 
of CO2 in the chamber, we introduced a bias flow using the 150 ml/min suction of a 
Normocap® CO2-sensor (Datex, Instrumentarium Oy, Helsinki, Finland), thus the 
CO2 concentration could be kept below 3%. Pressure measurements were semi-
automatically analyzed by the threshold search event detection method of “clampfit” 
(Molecular Devices, Sunnyvale, CA). Breathing frequencies were calculated as the 
reciprocal of the averaged inspiratory interval. The Coefficient of variation was 
calculated for the interval (CV = STD/mean). Furthermore the irregularity score (IS) 
was calculated (IS = 100*ABS(Intn- Intn-1)/Intn-1 for each respiratory cycle. 
 
3.2.3. Cell culture 
Adherent mouse N1E-115 neuroblastoma cells obtained from the American Type 
Culture Collection (ATCC) were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf serum (FCS, heat inactivated for 30 min at 
56°C) and 1% penicillin/streptomycin at 37°C under 5% CO2 in 10 cm dishes. Cells 
were splitted every 2 to 3 days depend on the confluence. Therefore, the medium 
was removed and the cells were washed with 37°C pre-warmed PBS and then cells 
were rinsed off mechanically and thoroughly resuspended 1 : 3 to 1 : 5 in fresh 
DMEM. 
 
3.2.3.1. Cell seeding  
Cultured cells were harvested and thoroughly separated before counting by means of 
Neubauer counting chamber using light microscopy. Cell concentration was adjusted 
to 500,000 cells/ml in pre-warmed culture media. Total volume of seeding was 
depending on the approach and the well size and is indicated in the table. Cells were 
incubated at 37°C under 5% CO2 overnight to allow attachment on the bottom or 
coverslip.  
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4-well / 2 100,000 0.5 Imaging 
6-well / 9.6 500,000 2 Protein, cAMP, luciferase 
promotor, and [35S]GTPγS assay 
IBIDI / 9.6 500,000 2 Imaging 
 
 
3.2.3.2. Transient transfection of N1E-115 cells 
4 - 7 µl Lipofectamine2000 reagent and 1 to 2 µg of expression plamids were 
separately mixed with 25 or 200 µl Optimem media. After incubation for 5 min at RT 
both batches were mixed and incubated for further 10 to 20 min at RT. Culture 
medium from overnight seeded cells was replaced by 200 or 500 µl Optimem. 50 or 
400 µl mixture was added to the cells drop-wise and incubated for 4 h to 6 h at 37°C 
under 5% CO2. Afterwards Optimem was replaced by DMEM and the cells were 
incubated overnight at 37°C under 5% CO2.  
 
3.2.3.3. Pharmacological treatment of cells - measurement of cAMP 
The second messenger cyclic 3’,5’-adenosine monophosphate (cAMP) has great 
relevance in many intracellular signal transduction cascades. It is ubiquitously 
present in animal, as well as in bacteria, and plants (Gerhring, 2010). Cyclic AMP is 
biologically synthesized from ATP by the adenylyl cyclase and is inactivated through 
enzymatic cleavage by the phosphodiesterase.  
In order to measure the influence of inhibitory G-protein coupled serotonin receptors 
on the intracellular cAMP concentration, first the cell system has to be activated.  
Therefore, transfected cells from 6-well plates were harvested and washed twice with 
pre-warmed DBPS. Afterwards cells were incubated in 1 ml Optimem in the presence 
of 10 µM forskolin to elevate cAMP concentrations for 10 min at 37°C while shaking. 
Next, cells were again incubated for 10 min at the same conditions in presence or 
absence of 10 µM serotonin. After pelleting the cells for 5 min at 800 xg, cells were 
diluted in cAMP lysis buffer -provided by Kit- and incubated on ice for 30 min or 
stored at -80°C.  
To measure cAMP in cells as well as in mouse tissue accurately the ELISA-based 
DetectX Direct Cyclic AMP was used according to the regular format of 
manufacture’s protocol. 200,000 cells were employed. Finally, optical density was 
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measured at 450 nm using Infinite M200 PRO luminometer. Cyclic AMP 
concentrations were calculated by plotting against of known cAMP concentration of a 
standard curve ranging from 0.616 to 150 pmol/ml. Afterwards concentrations were 
related to the total protein amount of each sample, which was measured using DC 
Protein Assay (refer to 3.2.5.2.). 
 
3.2.4. Molecular biology 
 
3.2.4.1. Isolation of nucleic acid 
 
3.2.4.1.1. Isolation of whole RNA 
In order to quantify gene expression or for cloning an open reading frame of a gene 
of interest first RNA was isolated from fresh mouse brain tissue using Trizol® 
reagents. Therefore, various brain regions were dissected under visual control using 
a cryostat and transferred to 900 µl Trizol®. Next, tissue was homogenized using 
hand mortar and incubated for 5 min at RT. After adding of 200 µl chloroform 
samples were vortexed and incubated for 5 min more at RT. Next, samples were 
centrifuged at 17,900 xg and 4°C for 10 min and the upper transparent phase (≈ 600 
µl) was mixed with equal volume of isopropanol and 1 µl GlycoBlue™ (Ambion) in 
order to precipitate and visualize the RNA. Samples were incubated at -28°C for 20 
min and thereafter centrifuged at 17,900 xg and 4°C for 20 min. Resulting RNA 
pellets were washed twice using 75% EtOH. After drying the RNA pellets were 
resuspended in 43.5 µl nuclease-free water (Ambion). In order to avoid DNA 
contamination a DNA digestion mix (5 µl 10x DNase I buffer, 1 µl DNase and 0.5 µl 
RNaseOut™) was added to the samples, which were then incubated at 37°C for 15 
min. The RNA was again extracted using phenol/chloroform method. Therefore, 150 
µl RNase-free water and 200 µl Roti® phenol (containing phenol / chloroform / 
isoamylalcohol; 25 : 24 : 1) were added to the samples and briefly vortexed. After 
centrifugation at 10,000 xg for 5 min the upper phase (≈200 µl) was mixed with equal 
volume of isopropanol and 1 µl GlycoBlue™ and incubated at -28°C for 20 min. After 
centrifugation at 4°C and 17,900 xg for 20 min resulting RNA pellets were washed 
twice with 75% EtOH. After drying the pellet RNA was eluted in appropriate volume 
of RNase-free ddH2O and the RNA concentration was determined by 
spectrophotometric analysis. To determine the integrity RNA was loaded and 
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separated in an agarose gel. RNA of good quality shows two distinguish bands of 
which the upper band (28S rRNA) has an as twice as much intensity the lower band 
represented by the 18S rRNA. RNA was subsequently transcribed into 
complementary DNA (cDNA) and afterwards stored at -80°C. 
 
3.2.4.1.2. Isolation of DNA from mice tails 
In order to determine the genotype of newborn mice DNA was isolated from biopsies 
of mice tails, incubated in 25 mM NaOH / 0.2 mM EDTA for 3 h at 99°C while shaking 
at 1,000 rpm. After neutralization with equal volume of 40 mM Tris/HCl pH 5.5 and 
centrifugation for 10 min at 10,000 xg, 1 µl was taken as template in a subsequent 
PCR.  
 












Plasmids were multiplied in Escherichia coli strain DH-5α library efficiency (Invitrogen 
GmbH, Karlsruhe). 
 
3.2.4.1.3.1. Heat shock transformation of bacteria 
DH-5α library efficiency bacteria suspensions (Invitrogen) were stored in 50 µl stocks 
at -80°C. For plasmid transformation stocks were shortly thawed on ice, gently mixed 
with 10 ng of plasmid or 1 µl of 1 : 3 diluted ligation reaction and incubated on ice for 
25 minutes. After heat shocking at 42°C for 45 s bacteria were replaced on ice for 
further 2 min. Next, bacteria were suspended in 450 µl SOC medium and incubated 
at 37°C for 60 min while shaking at 600 rpm. Afterwards bacteria were centrifuged at 
LB-medium  
10 g/l  Tryptone 
5 g/l Yeast extract 
5 g/l NaCl 
 
LB-plate  
10 g/l  LB-medium 
2% w/v Agar 
 
SOC-medium  
20 g/l  Tryptone 
5 g/l Yeast extract 
10 mM NaCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose 
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10,000 rpm for 1 min and 400 µl supernatant was removed. Bacteria were 
resuspended in the remaining volume (≈ 100 µl) and spread on ampicillin-containing 
LB-agar plates. After incubation at 37°C for 12 to 16 h, resulting colonies were 
analyzed for insert-specific plasmids using colony PCR.  
 
3.2.4.1.3.2. Isolation of plasmid DNA 
In order to obtain larger amounts of plasmid DNA, bacteria colonies were transferred 
to 5 ml LB medium (containing 1 µg amp for selection; for even higher amounts of 
plasmid DNA 50 ml of LB medium in presence of 10 µg amp was inoculated 1 : 1,000 
from an overnight pre-culture). After 14 to 16 h at 37°C while shaking at 130 rpm 
bacteria cultures were centrifuged at 4,000 xg for 10 min at RT. To isolate the 
plasmid DNA from the bacterial pellets QIAquick® for the 5 ml or HiSpeed® Maxi Kit 
for the 50 ml batch were used according to manufacturer’s instructions. 
Both kit procedures are based on the alkaline lysis of bacterial cells and subsequent 
isolation of plasmid DNA by adsorption onto silica membrane in presence of high salt 
(Birnboim & Doly, 1979; Vogelstein & Gillespie, 1979). The elution was made in 50 µl 
for 5 ml batch or 1 ml ddH2O for 50 ml batch.  
 
3.2.4.2. Spectroscopic determination of nucleic acid concentration 
The concentration of RNA and DNA was determined by spectrophotometric 
measurement of the wavelength absorbance at 260 nm using Nanodrop1000 
spectrophotometer. An optical density of 1.0 corresponds with 40 µg/ml single-
stranded RNA or 50 µg/ml double-stranded DNA, respectively. As aromatic amino 
acids have an absorbance maximum at 280 nm the ratio of 260 to 280 was taken as 
a purity grade. Protein-free nucleic acid samples have a ratio between 1.7 and 2.0.  
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Agarose gel electrophoresis was used to determine the integrity of RNA and to 
estimate the size of double-stranded DNA molecules by means of a size standard. 
Therefore, a 1.5% w/v (in 1x TAE buffer) agarose gel containing 0.4 µg/ml ethidium 
bromide was overlaid with 1x TAE buffer. DNA samples (at least 100 ng of DNA) 
were mixed with 6x DNA loading buffer, loaded onto the gel and then separated 
applying a voltage of 5 V/cm electrodes distance. DNA bands were visualized in UV-
light using a BIO-VISION™ fluorescence documentation system.  
 
3.2.4.4. Transcription of RNA into cDNA by reverse transcriptase   
The transcription of RNA into complementary DNA (cDNA) is a precondition to 
amplify RNA. The reverse transcriptase originally isolated from the Moloney Murine 
Leukemia Virus (MMLV) has an intrinsic RNA as well as a DNA depending 
polymerase activity. 0.5 or 1 µg RNA per reaction were transcribed using iScript™ 
cDNA synthesis kit according to manufacture’s instruction. The reaction was made in 












2 M Tris 
5.7 % (v/v) Acetic acid 
50 mM EDTA 
pH  8.0 
 
    20 µl Transcriptase reaction 
4 µl 5x iScript reaction mix 
1 µl  Reverse transcriptase 
x µl RNA (0.5 or 1 µg) 
ad 20 µl Nuclease-free water 
 
   Transcriptase reaction protocol 
4 min 25°C 
30 min  42°C 
5 min 85°C 
∞ 4°C 
 
10 x DNA Loading buffer 
250 mg Xylencyanol 
250 mg Orange 6 
ad 33 ml 150 mM  Tris pH 7.6 
60 ml (v/v) Glycerine 
ad 100 ml H2O 
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3.2.4.5. Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR), which was invented by Mullis et al. (1986), is 
an effective method to amplify double-stranded DNA using a thermo-stable DNA 
polymerase. Here, PCR was used for gene cloning and detection of specific DNA 
sequences by using corresponding primers. Depending on the approach two different 
polymerases were used. The Phusion® polymerase (NEB), which has a 50-fold lower 
error rate than the Taq polymerase (isolated from Thermus aquaticus), was taken for 
gene cloning, whereas Taq polymerase (PANScript red, PAN) was used for 









Step  Cycles Duration Temperature [°C] 
Initial denaturation 1 3 min 95 
Denaturation (optional)  
3 
30 s 95 
Annealing (optional) 30 s 60 - 63 
Elongation (optional) 45 s - 1 min 15 s 72 
Denaturation  
35 - 40 
30 s 95 
Annealing 30 s 64 - 68 
Elongation 45 s - 1 min 15 s 72 
Final elongation 1 5 min 72 
Hold 1 Infinite 10 
PCR reaction mix (PANScript red) 
1x  NH4 reaction buffer 
2 mM MgCl2 
0.2 µM Forward primer 
0.2 µM Reverse primer 
1 mM dNTPs 
0.02 U/µl Taq red 
10 - 50 ng  DNA template 
 
PCR reaction mix (Phusion®) 
1x  GC reaction buffer 
0.25 µM Forward primer 
0.25 µM Reverse primer 
1.25 mM dNTPs 
0.02 U/µl Phusion 
10 - 50 ng  cDNA template 
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Colony PCR 
To identify plasmid-insert positive bacteria colonies, they were separately picked and 
resolved in 10 µl ddH2O. 5 µl were taken for inoculation of 500 µl pre-culture. The 
remaining 5 µl served as template in a subsequent PCR with sequence specific 
primers. 
 
3.2.4.6. Quantitative real time PCR (q-PCR) 
The quantification of mRNA of various genes was measured by q-PCR using 
CFX96™ Real-time System and after (BioRad) and the Fast SYBR® Green Master 
Mix (AppliedBiosystem). 0.75 µl of corresponding cDNA was used as template in a 









The fluorescence dye SYBR® Green intercalates with double-stranded DNA, which 
occurs after every elongation cycle. The fluorescence is proportional to the amount of 
double-stranded PCR products and increases exponentially depend on the property 
of the PCR. When the fluorescence signal is exceeding the background level the 
cycle number is called the threshold cycle (CT), which is a measure for the amount of 
a specific cDNA initially present in the sample. Calculations of gene expression were 
performed using the 2-ΔΔCt method according to Pfaffl et al. (2001). Hypoxanthine 
guanine phosphoribosyl transferase (Hprt) and glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) served as reference genes (“housekeeping genes”) in the q-
PCR, which were performed using the following cycle conditions. 
  
q-PCR reaction mix  
5 µl  2x Fast SYBR® Green Master Mix 
0.2 µl Forward primer (200 nM; final concentration) 
0.2 µl Reverse primer (200 nM; final concentration) 
0.75 µl  cDNA template (derived from RNA) 
ad 10 µl ddH2O 
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Reference genes were run in duplicates, genes of interest in triplicates. 
 
3.2.4.6.1. Q-PCR Primer design  
Specific primer sequences are indispensible for an accurate q-PCR. Sense and 
antisense primer were derived by means of Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), which is based on the Primer3 








Resulting PCR amplicons were analyzed by agarose gelelectrophoresis, isolated, 
purified, and subsequently sequenced and blasted to confirm the correct identity. The 
primer efficiency was determined using 4-fold serial dilutions generated from cDNA of 
each sample. The amplicon of used primer pairs showed a single peak in the melting 
curve analysis. 
 
3.2.4.7. Molecular cloning of open reading frames from different serotonin 
receptors 
In order to analyze the molecular behavior of serotonin receptors in vitro the open 
reading frame of Htr1a, Htr7, Htr5a, and Htr5b as well as their truncated forms were 
cloned and fused to different fluorescent proteins. These constructs were ligated into 
Step  Cycles Duration Temperature [°C] 
Enzyme activation 1 3 min 95 
Denaturation   
40 
5 s 95 
Annealing / elongation 30 s 60  
Detection   
Melting curve 1 
10 s 95 
in 0.5°C steps 65 - 90 
q-PCR primer conditions  
G/C content  ≥ 40% ≤ 60% 
Primer length ≥ 18 ≤ 21 nucleotides 
Melting temperature ≈ 60°C 
Amplicon length ≥ 75 ≤ 250 nucleotides 
 exon-spanning (at least one of the primers) 
 C or G at the 3’ end 
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the mammalian expression plasmid pcDNA3.1(-) and expressed in N1E-115 cells. 
Figure 3.1 shows a schematic representation of the established cloning strategy, 












Figure 3.1. Schematic representation of the used cloning strategy.  
The coding sequence (CDS) for different serotonin receptors 5-HTX was ligated between the 
endonuclease restriction site BmtI and EcoRI. The Stop codon was deleted to achieve a continuous 
open reading frame (ORF) with the CDS from fluorescent proteins, which was cloned between the 
endonuclease restriction site EcoRI and HindIII. The start-ATG from the CDS of the fluorescent protein 
was deleted to avoid alternative protein translation. A linker between the two CDS was introduced 
consisting of three alanine residues (ala). The fusion construct was ligated into the mammalian 
expression vector pcDNA3.1(-). 
 
3.2.4.7.1. Gelextraction of DNA fragments 
First, the ORF of specific genes or fluorophores were amplified with appropriate 
primer pairs (refer to 3.1.9) by PCR and separated on an agarose gel. Specific bands 
were precisely excised and extracted using QIAquick® Gel Extraction kit following the 
manufacture’s protocol. Isolated DNA was eluted in 30 µl of nuclease-free ddH2O 
(Ambion). 
 
3.2.4.7.2. Restriction digest of DNA molecules 
The insertion of specific endonuclease restriction sites at both ends of an ORF by 
specific cloning primers enables site-directed insertion into a plasmid. Therefore, 3 
µg of pcDNA3.1(-) plasmid or 1 µg of gene or fluorophore ORF were double digested 
with restriction endonucleases as followed: 
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To avoid self-ligation 1 µl of FastAP™ alkaline phosphatase (Fermentas) was added 
to the plasmid reaction digest. Then, reactions were incubated at 37°C for 3 h and 
afterwards heat inactivated at 75°C for 20 min. Subsequently the restricted DNA was 
purified. 
 
3.2.4.7.3. Purification of DNA fragments 
Purification of DNA from restriction endonucleases and following PCR reactions were 
performed using QIAquick PCR Purification (Qiagen) according to manufacture’s 
instructions. DNA was eluted in 30 µl of nuclease-free ddH2O (Ambion) and 
afterwards the concentration was measured using Nanodrop1000.   
 
3.2.4.7.4. Ligation of DNA molecules  
A triple ligation was performed to generate a HtrX-fluorophore fusion ORF inserted 












Final volume [µl] 
pcDNA3.1(-) plasmid (3 µg) BmtI (0.8 u/µl)  
HindIII (0.8 u/µl) 
2 50 
HtrX insert (1 µg) BmtI (1 u/µl) 
EcoRI (1 u/µl) 
2 30 
Fluorophore insert (1 µg) EcoRI (1 u/µl) 
HindIII (1 u/µl) 
2 30 
 
Ligation reaction mix  
100 ng   pcDNA3.1(-) plasmid 
3 : 1 (molar ratio over plasmid) ORF HtrX 
3 : 1 (molar ratio over plasmid) ORF fluorophore 
2 µl 10x T4 DNA ligase buffer 
1 µl  T4 DNA ligase (Fermentas) 
ad 20 µl Nuclease-free ddH2O (Ambion) 
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Reactions were incubated at RT for 1 h and then heat inactivated at 75°C for 5 min. 
Afterwards reactions were diluted 1 : 3 with TE buffer. 1 µl was taken for 
transformation into DH5α competent bacteria. 
 
3.2.4.8. Identification of recombinant DNA by PCR based cycle sequencing 
To ensure the correct integrity of recombinant DNA, isolated plasmids were 
sequenced by cycle sequencing, which was conducted by SeqLab (Göttingen).  
Therefore, 700 ng of plasmid was diluted with 20 pmol forward or reverse primer and 
filled up to 7 µl with ddH2O (Ambion). Obtained sequences were blasted by means of 
SerialCloner sequence software. 
 














FA lysis buffer 
50 mM  HEPES 
140 mM NaCl 
1 mM EDTA 
1% (v/v) Triton X-100 
0.1% Sodium desoxycholate 
0.1% SDS 
1% (v/v) Protease inhibitor cocktail 
(fresh; Fermentas) 
pH  7.5 
 
RIPA buffer 
50 mM  Tris 
150 mM NaCl 
2 mM EDTA 
1% (v/v) IGEPAL CA-630 
0.5% Sodium desoxycholate 
0.1% SDS 
1% (v/v) Protease inhibitor cocktail 
(fresh; Fermentas) 
pH  8.0 
 
Wash buffer (low salt) 
20 mM  Tris 
150 mM NaCl 
2 mM EDTA 
1% (v/v) Triton X-100 
0.1% SDS 
pH  8.1 
 
Wash buffer (high salt) 
20 mM  Tris 
500 mM NaCl 
2 mM EDTA 
1% (v/v) Triton X-100 
0.1% SDS 
pH  8.1 
 









In order to test protein-DNA interactions in situ the pre-BötC was dissected from both 
sides of corresponding 300-µm-cryosections and immediately cross-linked in 1.5% 
formaldehyde/PBS for 15’ at RT. After quenching the reaction with 0.2 M Glycine, 
and washing 3 x with ice cold PBS, chromatin was solubilized and extracted in FA-
buffer for 20 min on ice and subsequently shared into 800 - 1,500 bp fragments by 
sonication for 15 x 25 s at 0.7 duty and 55 W. 1 : 10 dilutions in RIPA-buffer were 
pre-cleared by adding 1.5% (v/v) protein A slurry (Millipore) for 30 min at 4°C with 
rotation. Afterwards samples were incubated at 4°C with rotation overnight in 
presence of either 3 µg anti-MeCP2 antibodies (Abcam), 3 µg guinea pig anti-rabbit 
IgG (ZYMED, California, USA) or without antibody as negative control. To isolate 
immunocomplexes 4% (v/v) protein A slurry (Matrix) was added and incubated for 
further 1.5 h at 4°C. Matrix was washed 3 times with low salt, high salt, and LiCl 
wash buffer followed by additional 2 times TE buffer. After elution in freshly prepared 
1% SDS / 0.1 M NaHCO3, chromatin was reversely cross-linked by adding 0.2 M 
NaCl and incubated at 65°C and 1,000 rpm overnight. Subsequently, DNA was 
recovered by phenol/chloroform extraction, which was already described in 3.2.4.1.1. 
Amounts of precipitated DNA were subsequently analyzed using real-time PCR. 
 









Wash buffer (LiCl) 
10 mM Tris 
250 mM  LiCl 
1 mM EDTA 
1% Sodium desoxycholate 
1% (v/v) IGEPAL CA-630 
pH  8.1 
 
Reaction buffer 
50 mM Tris 
100 mM  NaCl 
2 mM EDTA 
3 mM MgCl2 
1 µM GDP 
pH  7.4 
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The radioactive [35S]GTPγS assay was performed in cooperation with Dr. Ute 
Renner, a former employer of the department of Neuro- and Sensory Physiology. 
Membrane preparations of transiently transfected N1E-115 cells expressing the 5-
HT5BR linked to mCherry fluorophore and G-protein α subunits (Gi3 and Gs fused to 
variants of eGFP) were performed according to the protocol described by Kvachnina 
et al., 2009. Agonist-promoted binding of [γ35S]guanosine 5-thiotriphosphate to 
different G proteins induced by stimulation of 5-HTR5B was performed as follows: 
Membrane preparations were diluted in reaction buffer to a concentration of 1 µg/µl. 
Each reaction contained 50 µg membrane preparations in a total volume of 100 µl. 
Reactions were performed in triplicate. After adding [35S]GTPγS (Hartmann Analytic) 
to a final concentration of 3 nM, samples were incubated for 5 min at 30°C in the 
presence or absence of 1 µM 5-HT. The reaction was terminated by adding 900 µl of 
RIPA-buffer (see 3.2.4.9.) for 30 min on ice. Samples were centrifuged at 13,000 xg 
for 10 min. The supernatants were then transferred into a new tube and samples 
were agitated for 2 h after addition of 100 µl protein A-Sepharose (Sigma, 20 mg/ml 
RIPA) and 0.5 µl of anti-GFP antibodies. Immunoprecipitates were washed three 
times, boiled in 0.5 ml of 0.5% SDS, and radioactivity was measured by scintillation 
counting. 
 
3.2.4.11. Luciferase reporter assay 
The Htr5b promoter-luciferase reporter, in which a 4.8 kb mouse Htr5b promoter 
DNA fragment was linked to the firefly luciferase gene (kindly provided by Prof. 
Maekawa from RIKEN Tsukuba Institute, Japan). One µg of promoter construct 
together with various amounts (0, 1, or 2 µg) of Mecp2 expression plasmid and 100 
ng of the renilla luciferase expression construct, which served as transfection control 
and reference protein activity, were co-transfected into N1E-115 cells from 6-well 
plates. Promoter activity was measured after 16 - 24 h using Dual-Luciferase® 
Reporter Assay System (Promega) according to manufacture’s instructions. 
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Brainstem tissues were homogenized before diluted with 500 µl PBS and 
supplemented with protease inhibitor cocktail (Fermentas). An equal volume of Triton 
X-100 lysis buffer was added to the homogenate. The lysis was performed on ice for 
30 min with occasional vortexing. After a high-speed centrifugation (100,000 xg) for 1 
h at 4°C, removal of the detergent using trichloro-acetic-acid (TCA)-precipitation, and 
subsequent two-times washing with acetone, the protein content was quantified using 
DC Protein Assay (BIO-RAD). Sandwich-ELISA procedures were established for the 
quantification of methyl-CpG binding protein 2 (MeCP2). Both used mouse 
monoclonal anti-MeCP2-antibodies (clone Men-8, Cat. No. M7443, Sigma-Aldrich) 
for capturing and rabbit polyclonal anti-MeCP2-antibodies (Institute of Human 
Genetics, University of Göttingen, Germany) in combination with a horseradish 
peroxidase (HRP)-conjugated secondary antibody (Code No. 711-035-152, Dianova) 
for detecting the antigen. Monoclonal anti-MeCP2-antibodies were diluted in coating 
buffer at a dilution of 10 µg/ml. The microtiter plate was coated with 100 µl antibody 
solution/well at 4°C overnight. The plate was washed five times with 300 µl washing 
buffer/well. 250 µl blocking solution (2% BSA dissolved in PBS) was added and 
applied for 30 min at RT to inhibit non-specific binding sites. The MeCP2-ELISA was 
standardized using purified MeCP2-protein (PharmedArtis, Aachen). ABTS was used 
as the chromogenic reagent. ABTS functions as electron donor whereby the 
substrate H2O2 of the enzyme peroxidase becomes reduced. Since the peroxidase-
catalyzed conversion follows a short linear kinetic, the color development was 
measured at different times (5, 10, 15, 20, 30, and 40 min) after the beginning of the 
enzyme reaction. The specific absorbance was measured at 405 nm (reference 
wavelength 492 nm). 
 
Triton X-100 lysis buffer 
50 mM Tris 
2 M  NaCl 
3.6 % Triton X-100 
pH  8.0 
 
Coating buffer 
16 mM NaHCO3 
34 mM  Na2CO3 
pH  9.6 
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3.2.5. Protein biochemistry 
 










Brain regions of interest were dissected from freshly frozen brains under visual 
control and immediately grinded up in adequate amounts of SDS lysis buffer using a 
hand pestle. 5 µl Benzonase® (Sigma-Aldrich) was added to remove nucleic acid 
contamination. Extractions were kept on ice for 30 min with periodical vortexing. 
Lysates were centrifuged for 20 min at 10,000 xg and 4°C. The supernatants were 
collected and quantified for protein concentration using a BSA standard curve. 
 
3.2.5.2. Determination of protein concentration 
Protein concentration was determined using the DC Protein Assay (BIO-RAD), which 
tolerates high SDS concentrations. The test is based on protein determination 
according to Lowry (Lowry et al., 1951). The reaction between copper and proteins in 
an alkaline environment leads to a reduction of the Folin’s reagent, mainly caused by 
aromatic amino acid residues, such as tyrosine and tryptophan, which are present in 
the protein. This method, which is ten to twenty times as sensitive as measurement 
of the ultraviolet light absorbance at 280 nm and about 100 times as sensitive as the 
biuret reaction, leads finally to an intensive blue staining, which can be measured by 
light absorbance at 690 nm.   
 
Kits provided Buffer 
Buffer A, reagent S, working reagent S’ (Mixture of A and S 20 : 1), Buffer B 
 
SDS Lysis puffer 
50 mM Tris 
150 mM NaCl 
2 mM EDTA 
2% (w/v) SDS 
1% (v/v) IGEPAL CA-630 
5 u Benzonase® 
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First, a BSA standard curve with samples of known protein concentrations, ranging 
from 200 - 1,500 µg/ml was prepared in lysis buffer. 5 µl of standard or 1 : 4 diluted 
protein lysate were added to 25 µl S’ and briefly mixed. After addition of 200 µl buffer 
B reactions were briefly agitated and incubated for at least 15 min at RT. The 
resulting color change was measured by absorbance at 690 nm using Nanodrop1000 
photometer. The protein concentrations were calculated by blotting extinctions 
against known BSA standards by means of the Nanodrop1000-internal software. All 
standards as well as protein samples were run in triplicates. After protein 
determination samples were adjusted to protein concentration of 2 µg/µl.  
 










The constant intercalation of the negative charged dodecyl sulfate into native 
proteins (1.4 g SDS per 1 g protein) leads to a masking of their own net charge and 
to linearization. This enables the separation of proteins according to their molecular 
size in an electric field during poly acrylamide electrophoresis (Laemmli, 1970; 
Laemmli & Favre, 1973). The relative mobility of a given protein is linearly depending 
on the logarithm of its relative molecular mass (Weber & Osborne, 1969). Protein 
lysates were mixed with 5x Laemmli sample buffer plus 10% of the reducing agent β-
mercaptoethanol and incubated for 10 min at 90°C. Subsequently 50 - 100 µ g of 
protein and 10 µl of Precision Plus Protein™ Kaleidoscope™ protein standard (BIO-
RAD) were loaded on precast polyacrylamide gel Novex® (4 - 20%) and separated at 
24 mA in presence of running buffer.  
 
  
5x Laemmli sample buffer 
250 mM Tris 
7% (w/v) SDS 
10 mM EDTA 
50% Glycerine 
50 mM EDTA 
7% (v/v) β-MercaptoEtOH (fresh) 
pH 6.8 
 
10 x Running buffer 
250 mM Tris 
2 M Glycine 
10% (w/v) SDS 
pH 8.3 
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3.2.5.4. Immunoblot and detection of specific proteins  
In order to prove particular proteins by a specific antibody, separated proteins of the 
SDS-PAG were transferred onto nitrocellulose membranes using the iBlot® -7-Minute 
Blotting System. In contrast to dry and semi-dry methods, buffer conditions and ions, 
required for the protein transfer, are provided by specific iBlot® Gel Transfer Stacks 
(Invitrogen). First, PAG was briefly washed in ddH2O and placed on the bottom 
anode stack, which contains an integrated 0.2 µm nitrocellulose membrane. 
Afterwards a ddH2O-soaked filter paper was placed on the PAG, the top cathode 
stack was placed, and air bubbles were removed. After assembling the iBlot® 
Disposable Sponge the proteins were plotted at 23 V for 7 minutes. To check the 
efficiency of the protein transfer the membrane was incubated in Ponceau solution 
for 1 min. After removing the Ponceau staining by washing the membrane in TBS-T 
three times (5 min each), the membrane was blocked in 5% BSA/TBS-T for 1 h at RT 
to inhibit non-specific binding sites. After washing 3 x 5 min with TBS-T the primary 
antibody was applied in appropriate concentrations (0.5 - 2 µg/ml) diluted in 2% 
BSA/PBS for 3 h at RT or alternatively at 4°C overnight.  
 
3.2.6. Fluorescence detection - confocal laser-scanning microscopy (CLSM) 
The confocal laser-scanning microscopy (CLSM) technique enables the detection of 
proteins in tissue sections using protein-specific antibodies, which are direct or 
indirect (by a secondary antibody) labeled with a fluorophore. The combination of 
fluorophores together with lasers of different wavelengths permits the simultaneous 
detection of different proteins or structures, respectively. Furthermore, this technique 
was used to localize recombinant fluorescent fusion proteins. For that, adherent 
transfected cells were fixed after 16 - 24 h with 2% PFA/PBS for 15 min at RT and 




Forty-µm-thick transversal sections ranging from the lumbar spinal cord to the pons 
were cut from fixed brains using a Frigomobil-cryostat (Reichert-Jung). Sections were 
washed three times in PBS 5 min at RT and then permeabilized with 0.2% Triton 
X-100/PBS for 30 min at RT. After washing 3 times with PBS non-specific binding 
sites were blocked with 5% BSA/PBS for 1 h at RT. After washing with PBS three 
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times of 10 min each, sections were incubated for 4 hours at RT or, alternatively, 16 
hours at 4°C in primary antibody solution (2% BSA/PBS, antibody concentration of 2 
- 5 µg/ml) followed by three washing steps for 15 min each. Sections were incubated 
for 3 hours at RT in the dark with species-specific secondary antibodies conjugated 
to various fluorophores, diluted 1 : 1,000 in 2% BSA/PBS. After extensive washing 
(three times, 15 min each) sections were mounted onto microscope-slides and 
coverslipped with fluorescent mounting medium. Neuronal immunofluorescence was 
analyzed with a confocal laser-scanning microscope META-LSM 510 (Zeiss, 
Germany) using laser lines at 405 nm (Diode laser), 488 nm (Ar/Kr laser), 543 nm 
(He/Ne laser), or 633 nm (He/Ne laser) alone or in combination. Wavelengths were 
separated by using the META module of the LSM. For data acquisition and analysis 
of confocal images the LSM 510 software (Zeiss, Germany) was applied. Images 
were taken at 2,048 x 2,048 dpi and were imported into Adobe Photoshop CS5, were 
digitally adjusted if necessary for brightness and contrast, and were assembled into 
plates.    
 
3.2.7. Electron microscopy 
In collaboration with Dr. Wiebke Möbius (Department of Neurogenetics, Max Planck 
Institute for Experimental Medicine, Göttingen) immunoelectron microscopy of 
ultrathin cryosections was performed as described previously (Feldmann et al., 
2011). In brief, wild type and MeCP2-deficient mice were anesthetized with 
isofluorane (1-Chloro-2,2,2-trifluoroethyl-difluoromethylether, Abott, Wiesbaden, 
Germany) and perfused transcardially with 4% formaldehyde (Serva) in 0.1 M 
phosphate buffer. Vibratome sections of the brainstem were infiltrated with 2.3 M 
sucrose in 0.1 M phosphate buffer over night. Small blocks from the region of the 
inferior olive and the VRG were mounted onto aluminum pins for ultramicrotomy and 
frozen in liquid nitrogen. Ultrathin cryosections were immunolabeled with rabbit 
antibodies specific for 5-HTR5B and protein A-gold (10 nm) obtained from the Cell 
Microscopy Center, Department of Cell Biology, University Medical Center Utrecht, 
The Netherlands. Sections were analyzed with a LEO EM912AB (Zeiss, 
Oberkochen) and digital micrographs were obtained with an on-axis 2,048 x 2,048-
CCD camera (TRS, Moorenweis). 
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3.2.8. Statistics 
Physiological experiments using the working heart brainstem preparation (WHBP) 
were statistically analyzed using repeated ANOVA with Bonferroni´s post-hoc test 
and were performed using GraphPad Prism. Differences were considered statistically 
significant at the p < 0.05 level. Data are presented as mean ± standard error of the 
mean (SEM) or standard deviation (SD) (n = number of experiments). To quantify the 
phrenic nerve activity (PNA) from electrophysiological recordings a representative 
measurement of one-minute duration before and after each drug application (15 min 
interval) was integrated with LabChart software. The coefficient of variation (CV in %) 
was used as an index for the relative variability (SD divided by the mean) of time 
durations analyzed for bursts per minute derived from integrated recordings of 





This chapter summarizes the contribution of the glycinergic and especially of the 
serotonergic system to the disturbed breathing in a mouse model for the Rett 
syndrome. This phenotype is fully developed at postnatal day 40 (P40). Furthermore, 
this section provides new insights into the regulation, characteristics, and function of 
the serotonin receptor 5B.  
 
4.1. Developmental expression of Mecp2 in the VRG 
To confirm a direct influence of MeCP2 on breathing disturbances in the Rett mouse 
we analyzed the expression of both Mecp2 mRNA in the VRG and the translated 
protein MeCP2 in the brainstem of wt mice at different developmental stages (P7, 
P15, P21, or P40). The bilateral-arranged VRG includes the pre-BötC, which is 
considered to be important for respiratory rhythm generation.  
 
4.1.1. Mecp2 mRNA expression in the VRG at different developmental stages 
To investigate the gene expression of Mecp2 in wt mice, first mRNA was isolated 
from the VRG at different developmental stages (P7, P15, P21, or P40) and 
transcribed into cDNA, which served as a template in a subsequent quantitative PCR 
(q-PCR). The relative amount of Mecp2 mRNA was high at the early stage P7 (1.876 
± 0.3505; fig. 4.1A) but significantly reduced at P15 (1.078 ± 0.2462; p < 0.05) and 
even lower at P21 (0.8437 ± 0.1841). At P40 the level of Mecp2 mRNA increased 
slightly again to 1.053 ± 0.1006. 
 
4.1.2. MeCP2 protein expression in the brainstem at different developmental 
stages 
In order to determine the developmental expression of MeCP2 protein quantitatively 
an enzyme-linked immunosorbent assay (ELISA) was developed and performed with 
protein lysate from brainstem of wt mice that includes the VRG. MeCP2 protein 
values were related to total protein content and indicated as (MeCP2/total protein) x 
10-7 in figure 4.1B. A high level of MeCP2 protein was detected at P7 as well as at 
P40, whereas in the intermediate stages P15 and P21 the protein expression was 
significantly lower. In comparison with the early stage P7 (12.00 ± 1.30), the relative 
amount of MeCP2 at P15 was significantly reduced to 9.80 ± 0.26 (p < 0.01) and 
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further decreased to 7.34 ± 0.13 (p < 0.001) at P21. At P40 the level of MeCP2 












Figure 4.1. Developmental gene expression of Mecp2/MeCP2 in wt mice.   
Mecp2 was measured quantitatively (A) at the RNA level in the VRG using q-PCR (n = 3) and (B) at 
the protein level in lysates from whole brainstem using ELISA procedure (n = 3) at 4 different 
developmental stages (P7, P15, P21, P40). The bar diagrams represent mean values and standard 
deviations (* = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001; one-way ANOVA). 
 
4.2. Identification of deregulated genes in the VRG 
As MeCP2 expression in wt mice is high at P40 it was concluded that MeCP2 has an 
influence on gene expression in the VRG at this particular developmental period 
when the disturbed breathing phenotype in MeCP2 deficient mice is fully developed. 
Therefore, mRNA expression from genes associated with the glycinergic and the 
serotonergic system, which are important for respiratory network activity (Richter et 
al., 2003), was investigated using q-PCR from total RNA of the VRG.  
 
4.2.1. Q-PCR analysis of components of the glycinergic system 
Glycine is the most abundant inhibitory neurotransmitter in the brainstem (Lynch, 
2004). Reciprocal inhibition of antagonistically connected glycinergic neurons is the 
indispensable drive for the respiratory rhythm (Richter & Spyer, 2001). Simultaneous 
blockade of glycinergic and GABA-ergic inhibition suppresses breathing (Paton & 
Richter, 1995). To test whether disturbed breathing in the Rett mouse originate from 
alterations in glycinergic transmission, important components of the glycinergic 
system were analyzed for their mRNA expression in the VRG of Mecp2-/y mice in 
comparison with wt mice. The ionotropic glycine receptor has a pentameric structure, 
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composed of five integral membrane subunits (Kuhse et al., 1995), which are 
encoded by different genes.  
However, there was no significant change in the mRNA expression between wt and 
Mecp2-/y mice in the VRG at P40 (fig. 4.2), neither for the glycine receptor subunits 
α1 (Glra1), α2 (Glra2), α3 (Glra3), α4 (Glra4), nor for the β subunit (Glrb). The 
strongest expression was observed for the glycine receptor β subunit, whereas the 
α2 and the α4 subunit were hardly detectable. No alterations in the mRNA 
expression were also found for the vesicular glycine transporter 1 (Slc6a9) and the 
synaptic glycine transporter 2 (Slc6a5). The mRNA level of gephyrin (Gphn), which 
plays a role in the assembling of glycine receptors (Fritschy et al., 2008) revealed 
also no alteration. Taken together, none of the investigated glycinergic genes were 















Figure 4.2. Comparison of mRNA expression of the glycinergic system in wt vs. Mecp2-/y mice 
in the VRG at P40.  
Messenger RNA level was measured by q-PCR. The bar diagram represents mean values and 
standard deviation from n = 5 biological replicates of the glycine receptor subunits α1 (Glra1), α2 
(Glra2), α3 (Glra3), α4 (Glra4) and β (Glrb), the glycine transporter 1 (Slc6a9) and 2 (Slc6a3) and 






4.2.2. Quantification of mRNA expression of serotonergic components in the 
 VRG  
Serotonin (5-HT) is an important neuromodulator for breathing and its receptors (5-
HTR) are widely expressed in the respiratory network (Richter et al., 2003; Manzke et 
al., 2009). To investigate the putative influence of the serotonergic system on 
breathing disturbances in the Rett mouse, 5-HT receptors as well as serotonin 
transporters and enzymes involved in the biosynthesis of serotonin were investigated 
for their mRNA expression in the VRG at P40 and compared with wt, which was set 
to 1. Q-PCR analysis revealed that 4 of altogether 12 investigated serotonergic 
genes were deregulated in the VRG of Rett mice. The mRNA level of Htr2c was 
reduced to roughly a half compared with wt (wt vs. Mecp2-/y; 1.000 ± 0.073 vs. 0.481 
± 0.045; p ≤ 0.001), whereas the mRNA level for Htr1d (wt vs. Mecp2-/y; 1.000 ± 
0.197 vs. 2.230 ± 0.326, p ≤ 0.05) and dopamine decarboxylase (Ddc) (wt vs. Mecp2-
/y; 1.000 ± 0.157 vs. 3.590 ± 0.956, p ≤ 0.05) were increased by 2 or 3.5-fold, 
respectively. However, the strongest deregulation was observed for the Htr5b gene, 
which showed a 76-fold higher mRNA expression rate in the VRG of Rett mice in 
comparison with wt at P40. Because of deregulation of serotonergic genes in the 
VRG, especially the enormous alteration of the Htr5b gene, it was concluded that this 
might have effect on breathing disturbances in the Rett mouse. Hence, Htr5b was 





Figure 4.3. Comparison of mRNA expression of the serotonergic system in wt vs. Mecp2-/y 
mice in the VRG at P40.  
Messenger RNA level in the VRG was measured by q-PCR. The bar diagrams represent the results of 
separate q-PCR analysis with mean values and standard error of the mean from n = 3 biological 
replicates of genes for the serotonin receptors Htr1a, Htr1b, Htr1d, Htr2c, Htr2a, Htr3a, Htr4, Htr5a, 
Htr5b, Htr6, Htr7, the serotonin transporter (Slc6a4), and the enzymes dopamine decarboxylase (Ddc) 
and tryptophan hydroxylase 2 (Tph2). Asterisks indicate significance (* = p ≤ 0.05; ** = p ≤ 0.01; t-
test). 
 
4.2.2.1. Analysis of region specific Htr5b mRNA expression 
To clarify whether the Htr5b mRNA is ubiquitously up-regulated in the Rett mouse 
throughout the brain, q-PCR analysis was performed from various brain regions at 
P40 (fig. 4.4). Besides the VRG, a significant increase of Htr5b mRNA in the cortex of 
Rett mice was observed. In contrast to the strong up-regulation seen in the VRG (fig. 
4.3), this increase was only moderate by 2.5-fold compared to wt, which was set to 1 
(wt vs. Mecp2-/y; 1.00 ± 0.054 vs. 2.63 ± 0.105; p ≤ 0.001). Other regions investigated 
(cerebellum, hippocampus, and inferior olive) did not show any significant Htr5b 




Figure 4.4. Comparison of Htr5b mRNA expression in wt vs. Mecp2-/y mice from different brain   
regions at P40.  
Htr5b mRNA expression level from cortex, cerebellum, hippocampus, and inferior olive were 
measured by q-PCR. The bar diagrams represent mean values and SEM of n = 3 biological replicates. 
Wild type was set to 1. Asterisks indicate significance (*** = p ≤ 0.001; student´s t-test). 
 
 
Overall, a systemic alteration of Htr5b mRNA expression in the brain of Rett mice in 
comparison with wt mice was not observed at development stage P40. The strong 








4.2.2.2. Developmental expression of Htr5b in wt and Rett mice 
Q-PCR studies of Htr5b in the VRG were performed from 4 different postnatal 
development stages (P7 - P40). No differences in the Htr5b mRNA expression were 
detected between wt and Rett mice at P7, P15, and P21. As already shown in fig 4.3, 
an Htr5b dysregulation was observed only at P40, which correlates with the onset of 












Figure 4.5. Developmental mRNA expression profile of Htr5b in the VRG in wt compared to 
         Mecp2-/y mice. 
Htr5b expression level in the VRG was measured by q-PCR. The bar diagram represents mean value 
and SEM from n = 3 biological replicates at each development stage (P7, P15, P21, and P40) with 
asterisks indicating significance (** = p ≤ 0.01; one-way ANOVA). 
 
 
4.2.3. Protein expression of 5-HTR5B 
Information about the 5-HTR5B and its distribution throughout the brain is sparse. In 
situ hybridization revealed strong Htr5b mRNA expression in the intermediate layers 
of the entorhinal cortex, in the CA1 region and the parasubiculum of the 
hippocampus, and in the medial habenula. In the brainstem, Htr5b mRNA is 
abundantly expressed in the dorsal raphé nucleus and in the inferior olive (Serrats et 
al., 2004). 
In order to verify the results of Htr5b mRNA expression in the VRG at the protein 
level and to refine the localization of the 5-HTR5B protein within the respiratory 
network, immunohistochemistry was performed using both self-made and 
commercially available antibodies. The homemade antibody, which was produced in 
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our lab, was directed against the very last 11 amino acids of the C-terminal domain of 
the 5-HTR5B protein (NH2-KNYNNAFKSLFTKQR-COOH). This epitope is 100% 
homologous in all species including men. The antibody was tested on N1E-115 cells. 
5-HTR5B-IR was only detectable in cells transfected with Htr5b, whereas no signal 
was observed in non-transfected cells. The 5-HTR5B labeling was abolished by pre-
incubation of the primary antibody with peptides that were used for immunization 
indicating specificity. Hence, it was concluded that the antibody is reliable for 














Figure 4.6. Test for specificity of the peptide specific anti-5-HT5BR antibody. 
Htr5b-transfected and non-transfected N1E-115 cells were stained with a homemade anti-5-HTR5B 
antibody followed by a secondary Atto546-conjugated anti-rabbit IgG antibody. Fluorescence was 
visualized using CLSM. IR was only detectable in transfected cells. Scale bars = 100 µm. 
 
At P40 an abundant 5-HTR5B-immunoreactivity (-IR) was detected in the inferior olive 
and the nucleus raphé obscurus of both wt and Mecp2-/y mice, which is in 
accordance with the literature describing a strong Htr5b mRNA expression in these 
regions in rat (Serrats et al., 2004). In contrast, in the pre-BötC a strong 5-HTR5B 
expression was only observed in Rett mice, whereas the protein expression in the 





Figure 4.7. Comparison of 5-HTR5B protein expression in wt and Rett mice at P40.  
Representative images of 5-HTR5B immunoreactivity in the ventrolateral medulla from wt and Mecp2 
knockout mice. Sections from Htr5b null mice (Htr5b-/-) served as negative control. Schematic drawing 
shows where the sections were cut with the pre-Bötzinger complex (pre-BötC) and its anatomical 
landmarks such as the nucleus ambiguus (NA) and the principal nucleus of the inferior olive (IOPr). 




4.3. Regulation of Htr5b expression in the VRG  
MeCP2 is a transcription factor involved in epigenetical gene regulation (Guy et al., 
2011). As Htr5b is dysregulated between wt and Mecp2-/y mice in the VRG at P40, it 
was investigated whether MeCP2 directly causes these alterations. Recently, it has 
been reported that in mice experiencing social stress the Htr5b gene is under control 
of the transcription factor ATF-7 (Maekawa et al., 2010). As RTT is also 
accompanied with stress, we analyzed whether ATF-7 affects Htr5b mRNA 
expression in Rett mice. However, q-PCR performed from total RNA of the VRG 
region at P40 revealed no alterations in Atf7 mRNA expression between wt and Rett 
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mouse (1.0000 ± 0.0927 vs. 0.8725 ± 0.0465; fig. 4.8A). In addition, the mRNA level 
of the mitogen-activated protein kinase 14 (Mapk14), which activates ATF-7 by 
phosphorylation, was not changed significantly (1.0000 ± 0.0611 vs. 0.9316 ± 
0.04224; fig. 4.8A).  
 
 
4.3.1. Developmental expression of Htr5b in the VRG 
First evidence of a direct regulation of Htr5b by MeCP2 in the VRG was obtained 
from Htr5b mRNA expression in the VRG (fig. 4.5) when compared with MeCP2 
protein expression in the brainstem at different development stages (P7, P15, P21, 
and P40) (fig. 4.8B). In wt mice the MeCP2 protein level gradually decreased during 
P7 and P28. Simultaneously Htr5b mRNA expression was increased from 0.1496 ± 
0.0490 at P7 to 0.8839 ± 0.0255 (p ≤ 0.0001), whereas at P40 when the MeCP2 
protein level turned back to high level, the Htr5b mRNA was again greatly 
suppressed (0.00921 ± 0.0074). The reciprocal developmental profiles of MeCP2 













Figure 4.8. Regulation and developmental expression of Htr5b in wt and Rett mice. 
(A) Messenger RNA analysis of Atf7 and Mapk14 in the VRG at P40 of wt and Mecp2-/y mice. Bar 
diagrams show mean value and SEM of n = 5 biological replicates (student´s t-test). (B) Comparison 
of MeCP2 protein and Htr5b mRNA expression in wt mice during development stages P7, P15, P21, 
and P40. MeCP2 protein content was measured using ELISA procedure from brainstem lysates (n = 
3). Htr5b mRNA expression was measured in the VRG using q-PCR (n = 3). Htr5b mRNA level was 
increased at developmental stages when MeCP2 protein concentration was reduced, whereas low 
level of Htr5b was found at P7 and P40 when MeCP2 protein was high. 
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4.3.2. MeCP2 binds to the Htr5b promoter 
In order to test whether Htr5b is a direct target of MeCP2 we performed chromatin 
immunoprecipitation (ChIP) to test for putative MeCP2 binding within the proximal 
Htr5b promoter region. Therefore, protein-DNA interactions were fixed and shared 
into smaller fragments. MeCP2-precipitated DNA was purified and served as 
template in subsequent q-PCR analysis. For want of a defined putative MeCP2 DNA 
binding site we used 7 primer pairs, which bind along the 5.3 kb proximal Htr5b 
promoter (+5.0 kb to +0.2 kb before transcription start). At all investigated loci we 
found a significant difference between MeCP2 precipitated DNA using a MeCP2-
specific antibody, in comparison to controls. However, the highest amount of MeCP2-
precipitated DNA was detected at +4.7 kb. This was (3.6 ± 0.5)-fold compared to the 
IgG control, which was set to 1.0 (1.0 ± 0.5; p < 0.01), indicating an efficient MeCP2 
binding to the Htr5b promoter (fig. 4.9A). 
 
4.3.3. MeCP2 represses Htr5b expression in vitro 
To determine whether the observed binding of MeCP2 inhibits the expression of the 
Htr5b gene directly, we co-transfected luciferase reporter constructs driven by the 4.8 
kb up stream Htr5b promoter together with increasing amounts of Mecp2 expression 
plasmid (1 or 2 µg) into N1E-115 cells. Before performing a promoter-luciferase 
reporter assay (fig. 4.9B), the MeCP2 expression was verified using immunoblot 
analysis (fig. 4.9C). Higher amount of Mecp2 expression plasmid led to an increase 
of MeCP2 protein. In contrast to the MOCK control without MeCP2, luciferase activity 
was gradually decreased with increasing amounts of MeCP2 by approximately 30% 




























Figure 4.9. Direct regulation of Htr5b gene expression by MeCP2 in the VRG.  
(A) Chromatin immunoprecipitation (ChIP) analysis was performed using an anti-MeCP2 specific 
antibody. DNA was isolated from the VRG of wt mice. Quantification of MeCP2-precipitated DNA 
followed by q-PCR using 7 different primer pairs specific for different loci of the Htr5b promoter 
(schematically shown below the diagram). (B) Htr5b promoter luciferase assay. N1E-115 cells were 
co-transfected with Htr5b promoter and increasing amounts of Mecp2 expressions constructs. Bar 
diagram shows mean value and SEM of luciferase activity (n = 3). Asterisks indicate significance (* = p 
< 0.05; ** < 0.01; one-way ANOVA). (C) Representative MeCP2 immunoblot of N1E-115 cell lysates 
transfected with increasing amount of Mecp2 expression constructs. Glycerinaldehyd-3-phosphat-
dehydrogenase (GAPDH) served as reference protein and loading control. 
 
4.4. 5-HTR5B is expressed in human 
The Htr5b is abundantly expressed in the inferior olive of rodents (Serrats et al., 
2004). The gene exists in all mammalian species with exception of men where it is 
described as a pseudo gene (Grailhe et al., 2001). In contrast to rodents and other 
mammals the human HTR5B open reading frame is disrupted by 3 stop codons and 
repeated insertion in its 5’-region, which affects the N-terminal part of the protein (fig. 
4.11).  
Surprisingly, immunohistochemistry of human brainstem sections using self-made 
anti-5-HTR5B antibodies (fig. 4.6), which are directed against the C-terminal domain 
of the protein, revealed a strong signal in the inferior olive (fig. 4.10). Furthermore, 












Figure 4.10. Expression of the 5-HTR5B receptor in the human inferior olive.  
(A) Schematic representation of a human brainstem section with anatomical landmarks inferior olive 
(IO), nucleus of the solitary tract (NTS), and hypoglossal nucleus showing where the sections were 
taken from. (B) Representative human brainstem sections stained with anti-5-HTR5B antibody followed 
by an Atto546-conjugated secondary antibody. Immunofluorescence was finally visualized by CLSM. 
Strong IR was detected in the IO. Scale bars = 200 µm (overview) or 10 µm (clustered 5-HTR5B 




4.4.1. The serotonin receptor 5B is truncated 
Depending on the unexpected result of 5-HTR5B expression in human tissue, DNA 
sequence comparisons were carried out. The rodent Htr5b gene, which consists of 
two exons, revealed highly conserved second ATG in the 5’-region within the first 
exon in all species (4.11B). This ATG is in frame with the coding sequence, but the 
corresponding translation would result in a truncated protein containing only 197 of 
370 amino acids with a theoretical relative molecular mass of 22.5 kDa. Surprisingly, 
although the open reading frame (ORF) in rodents is not disrupted, 5-HTR5B 
immunoblot analyses of mouse and rat brainstem lysates revealed a specific band at 
about 23 kDa, which corresponds with the predicted truncated variant (fig. 4.11A). No 
signal was observed at 41 kDa, which is the expected relative molecular mass for the 
full-length receptor. Comparison of the truncated 5-HTR5B amino acids sequence 
starting with the methionine encoded by the second ATG reveled a high 
conservation, suggesting that the C-terminal part is of special functional importance. 
Related to mouse, rat, rabbit, and human orthologs showed 97%, 89%, or 85% 
homology, respectively (fig. 4.11C). Originally the 5-HTR5B has been classified as a 
member of G-protein coupled receptors, which possess seven transmembrane 
domains (Hoyer et al. 2002). 
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According to transmembrane domain analysis using TMHMM server 2.0 (fig. 4.11D), 
the truncated 5-HTR5B lacks the first three transmembrane domains including the 
serotonin binding site, which is originally located in the N-terminal part of the protein 
(fig. 4.11E). However, the putative G-protein binding site, which comprises the last 








Figure 4.11. Truncation of 5-HTR5B. 
(A) 5-HTR5B immunoblot analysis of brainstem lysates (80 µg total protein per lane) from mouse and 
rat (n = 3) and control (antibody blockade using antigen-specific peptide) using homemade anti-5-
HTR5B antibodies. A specific band was detected at approximately 23 kDa. (B) Schematic 
representation of the Htr5b gene with exon-intron structure. In men, the open reading frame is 
disrupted by insertion and nonsense mutations (marked as asterisks). Htr5b sequence comparison 
among species revealed a second start-ATG within the first exon. Translation would lead to a 
truncated protein of 197 amino acids with a predicted relative molecular mass of 22.5 kDa. (C) 
Comparison of the truncated 5-HTR5B amino acid sequence among 4 species using ClustalW 2.0 
revealed high homology. Percentages are related to mouse (100%). Asterisks under the amino acid 
mean 100% consensus. (D) Identification of membrane-located amino acids of the truncated 5-HTR5B 
using TMHMM server 2.0. Probability of 1.0 means 100% likelihood. Purple line means the domain is 
extracellular. Blue lines means the domain is intracellular. (E) shows a schematic model of the 
truncated 5-HTR5B based on the membrane prediction. The protein contains only the last 4 of naturally 




Overall, the expression of the protein in the human inferior olive, the immunoblot 
analysis of rodent brainstem lysates, and the strong phylogenetical conservation of 
the shortened variant of 5-HTR5B revealed evidence of the existence of a naturally 
expressed truncated GPCR. 
Although there was no evidence of a full-length receptor at all, for further 




4.5. Functions of 5-HTR5B 
The truncation of the 5-HTR5B protein raised the question whether this protein is still 
functional and where it is expressed within the cell. Therefore, both 5-HTR5B variants 
were cloned from mouse brainstem cDNA, cloned into the expression plasmid 






4.5.1. Unusual endosomal localization of 5-HTR5B in neurons 
To address the question of the 5-HTR5B localization, 1 - 2 µg of expression plasmid 
with different variants of Htr5b were transfected into murine neuroblastoma cells 
(N1E-115) and analyzed after 16 - 24 hours of incubation by confocal microscopy. In 
contrast to other investigated serotonin receptors, such as 5-HTR1A and 5-HTR7, 
which showed an expected cell membrane expression, 5-HTR5B was expressed in 
distinct intracellular clusters no matter whether the full-length or the truncated variant 
was analyzed (fig. 4.12). Expression analysis in other cell lines, such as human 
embryonic kidney (HEK) cells or monkey kidney Cercopithecus aethiops, origin-
defective SV-40 (COS-7) cells led to similar intracellular expression pattern. 
Interestingly, fusion constructs of Htr5a, which belongs to the same subclass as 
Htr5b, displayed also a clustered intracellular expression. However, contrary to Htr5b 





Figure 4.12. Localization of 5-HTR5B variants in overexpressing neuroblastoma cells.  
N1E-115 cells were transiently transfected with Htr1a-eGFP (green), Htr5bFL-mCherry, Htr5bTR-
mCherry, and Htr5a-mCherry fusion constructs (red). The lower panel shows cells at higher 
magnification together with DAPI nucleus staining (blue). EGFP and mCherry fluorescence were 
visualized directly using CLSM. Scale bars in the upper panel = 20 µm, in the lower panel = 10 µm. 
 
For identification of the exact localization of intracellular 5-HTR5B, fusion constructs of 
Htr5b were co-expressed in N1E-115 cells together with fluorescent marker 
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constructs, which are specifically located in characteristic subcellular compartments 
(fig. 4.13). Detailed analysis revealed a strong co-expression of 5-HTR5B with the 
endosome, but only a weak one with the lysosome or the endoplasmic reticulum. No 





















Figure 4.13. Identification of subcellular localization of 5-HTR5B protein in vitro. 
Representative images of Htr5bFL-mCherry (red) expressed in N1E-115 cells, which are co-transfected 
with fluorescent fusion constructs specific for subcellular compartments (green): pEYFP-Mem 
(membrane), pEYFP-Mito (mitochondria), pEYFP-Lamp1 (lysosome), pEYFP-ER (endoplasmic 
reticulum) and pEYFP-Rab7 (endosomes). Fluorescence was finally visualized using CLSM. Strong 
overlay was observed between 5-HTR5B and the endosomal compartment. Scale bars = 10 µm. 
 
To exclude that these results were produced by artifacts from overexpression and to 
confirm the localization in situ, electron microscopy was performed on brainstem 
sections of wt mice using an anti-5-HTR5B antibody. A specific signal was detected in 
cells of the inferior olive. However, the cell surface membrane did not show any 5-
HTR5B-IR (fig. 4.14A). Detailed analysis showed a signal associated to membranes 

























Figure 4.14. Intracellular localization of 5-HTR5B in situ. 
Representative cryo-immunogold staining visualized by electron microscopy. Images of different 
magnification show 5-HTR5B-IR in the inferior olive of wt mice at P40. (A) No 5-HTR5B-IR was 
observed in the cell surface membrane (dotted red line) in contrast to strong signals in the membrane 
of vesicular and tubular intracellular compartments (B, C; red arrows). Scale bars = 100 nm in A; 200 
nm in B; or 50 nm in C. 
 
Furthermore, immunohistochemistry performed on brainstem sections of GFAP-
transgenic mice, which express GFP under the control of the glial fibrillary acidic 
protein (Gfap) promoter, revealed no co-expression of 5-HTR5B and GFAP in the 
inferior olive (4.15A) and in the nucleus raphé obscurus (fig. 4.15B). Since GFAP is 







Figure 4.15. Neuronal expression of the 5-HTR5B protein. 
Representative staining of 5-HTR5B-IR (red) in the region of the (A) inferior olive (IO) and (B) nucleus 
raphé obscurus (ROb). Immunohistochemistry was performed on brainstem sections of mice, which 
express the green fluorescent protein (GFP) under the control of the glial fibrillary acidic protein (Gfap) 
promoter (green). DAPI nucleus staining (blue). Fluorescence was visualized using CLSM. There was 
no co-expression of GFAP and 5-HTR5B. Scale bars = 20 µm.  
 
Taken together, results of cryo-immunogold electron microscopy and CLSM of 
transfected cells as well as on brainstem sections using Gfap-transgenic mice 
revealed that 5-HTR5B is predominantly located in the membrane of intracellular 
vesicles. Furthermore, the truncated protein is naturally expressed in neurons but not 
in glial cells. 
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Since the truncated receptor lost its ligand-binding site and is not expressed on the 
cell surface membrane this protein is renamed as 5-HT5B to differentiate it from 




4.5.2. 5-HT5B affects localization of serotonin receptors 
Originally the serotonin receptor 5B belongs to G-protein coupled receptors (Hoyer et 
al., 2002). Some GPCRs such as dopamine receptor D2, the muscarinic receptor 
m3, GABA(B) R1 and GABA(B) R2 can interact and form heterodimers (Angers et 
al., 2002; White et al., 1998). However, there is only little information about 
interactions between serotonin receptors, which seems to be rather weak (Renner et 
al., 2012). Confocal microscopy of 5-HTR1A and 5-HT5B co-transfected N1E-115 cells 
revealed a strong co-expression of both receptors (fig. 4.16). 
 
The presence of 5-HT5B in 5-HTR1A expressing cells led to a de-localization of 5-
HTR1A from the plasma membrane into the same compartment where 5-HT5B was 
expressed. Furthermore, the efficiency of 5-HTR1A translocation was only depending 
on the expression level of 5-HT5B. This interaction was observed for both variants, the 
full-length and the truncated form of 5-HT5B to an equal extent. High 5-HT5B 
expression led to increased amount of intracellular 5-HTR1A, whereas a low level of 
5-HT5B showed only small amounts of co-expressed 5-HTR1A indicating that there 
might be a direct interaction in a certain stoichiometric ratio between both proteins. In 
contrast to 5-HT5B the 5-HTR5A, which showed also a predominantly intracellular 
expression pattern (fig. 4.12), had no effect on 5-HTR1A localization (fig. 4.16A).  
In contrast to the de-localization of 5-HTR1A, the cell surface expression of the 5-
HTR7 remained unaffected when co-expressed with 5-HT5B variants. No co-








































Figure 4.16. Serotonin 5B protein affects the localization of 5-HTR1A, but not 5-HTR7.  
(A) Full-length (Htr5bFL)-, truncated (Htr5bTR)-, or Htr5a-mCherry fusion constructs (red) were co-
transfected with Htr1a-eGFP or Htr7-eGFP fusion constructs (green) into N1E-115 cells. Fluorescence 
was analyzed after 16 - 24 hours using CLSM. 5-HTR1A remained intracellular in co-transfected cells 
and showed a strong co-expression with the 5-HT5B protein variants (yellow), while 5-HTR5A did not 
affect the localization of 5-HTR1A. (B) In the presence of 5-HT5B variants the 5-HTR7 cell surface 
expression remained unaffected. Scale bars = 20 µm. 
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4.5.3. Analysis of 5-HT5B signaling 
Previous data revealed that the 5-HT5B protein is truncated in which its first three 
transmembrane domains including the serotonin-binding site are absent. Although 
the putative G-protein interaction domain, which comprises the last two intracellular 
domains (Bockaert, 1991; Strader et al., 1995), does still exist according to the 
hypothetical model (fig. 4.11), it was unclear whether the truncated protein is capable 
to bind G-proteins. 
 
4.5.3.1. 5-HT5B couples to inhibitory heterotrimeric G-protein alpha 3 
To test whether 5-HT5B is still able to bind to G-proteins as well as to identify the type 
of interacting G-protein, N1E-115 cells were co-transfected with the full-length 5-HT5B 
variant and different classes of G-proteins. A subsequently conducted [35S]GTPγS-
assay revealed that in contrast to the baseline level the GTPγS binding signal was 
only minor increased by 1% when 5-HT5B was co-expressed with the stimulatory G-
protein Gαs, which was similarly low in the MOCK control (2%, fig. 4.17A). However, 
with 220% over baseline level a strong GTPγS-binding signal was observed for Gαi3 
when co-expressed with 5-HT5B. Only 39% was observed when Gαi3 was expressed 
alone indicating that 5-HT5B interacts with the inhibitory G-protein Gαi3. 
 
4.5.3.2. 5-HT5B reduces cAMP in vitro  
Due to the interaction with Gαi3, a negative effect on the cAMP concentration was 
assumed. For verification, N1E-115 cells were transfected with the 5-HT5B variants 
and the cAMP concentration was measured after 16 - 24 h. Compared to the MOCK 
control, which was set to 100%, the intracellular cAMP concentration of 5-HT5BTR 
and 5-HT5BFL-transfected cells were decreased to 55.38 ± 5.28% (p = 0.01) or 67.03 
± 7.76% (p = 0.05) without serotonin stimulation (fig. 4.17B). A similar reduction of 
cAMP was observed in 5-HTR1A transfected cells when activated with 10 µM 
serotonin (68.10 ± 5.90%, p = 0.05). In contrast, non-stimulated 5-HTR1A cells did not 


















Figure 4.17. Signaling of 5-HT5B. 
(A) Bar diagram represents mean value and SEM of GTPγS assay from n = 3 biological replicates. 
N1E-115 cells were single or co-transfected with 5-HT5B, Gαi3, and Gαs expression constructs, and the 
level of bound GTPγS was measured by scintillation. Non-transfected cells served as control. The 
strongest signal was observed when 5-HT5B and Gαi3 were co-transfected. (B) Effects of 5-HT5B 
variants on intracellular cAMP level. N1E-115 cells were transfected with no (MOCK) or with different 
serotonin receptor expression constructs and the cAMP level was activated by 10 µM of the adenylyl 
cyclase activator forskolin. Cyclic AMP was related to the protein content and biochemically measured 
in presence of 10 µM 5-HT for 5-HTR1A or in absence of 5-HT for both 5-HT5B variants. MOCK control 
was set to 100%. Bar diagram shows mean value and SEM of n = 3 biological replicates. Reduced 
cAMP levels were observed for cells transfected with 5-HT5B variants and serotonin-treated 5-HTR1A 




4.6. Characterization of a Mecp2-/y;Htr5b-/- double-knockout mouse 
To investigate the physiological consequences of the pathological strong 5-HT5B 
expression in the VRG of Rett mice, a Rett mouse additionally missing the Htr5b 
gene was generated by crossbreeding. The double-knockout mice (Mecp2-/y;Htr5b-/-, 
double-ko) were subsequently characterized for breathing disturbances and physical 
condition. 
 
The Htr5b knockout mouse (Htr5b-/-) did not display a conspicuous phenotype at 
least until an age of 400 days. Furthermore, individuals did not show any breathing 






4.6.1. 5-HT5B changes cAMP concentration in the VRG 
Depending on the observation that 5-HT5B is able to reduce cAMP constitutively in 
vitro it was asked, whether the cAMP concentration in the VRG of Rett mice is 
changed due to the pathological strong 5-HT5B expression at development stage 
P40. Therefore, the VRG was dissected and the cAMP concentrations were 
measured and adjusted to the protein content. The cAMP measurements revealed a 
significant lower concentration of cAMP in VRG lysates of Rett mice to 73.49 ± 
7.27% (p = 0.01) in comparison to wt, which was set to 100% (fig. 4.18). However, no 
significant change in the cAMP concentration was observed when comparing wt with 
double-ko mice (wt vs. Mecp2-/y;Htr5b-/-, 100 ± 4.58% vs. 98.46 ± 6.34%, n.s.).  
These observations indicated that the high expression of 5-HT5B in the VRG of Rett 










Figure 4.18. Comparison of cAMP level in the VRG at P40. 
The VRG was dissected at P40 and the cAMP concentration was measured and adjusted to the 
protein content of the sample. The bar diagram represents mean value and SEM of n = 5 biological 
replicates. Cyclic AMP concentration of wild type was set to 100% and was low in the VRG of Mecp2-/y 
mice but not changed in the Mecp2-/y,Htr5b-/- mouse. Asterisks indicate significance (* = p < 0.05; ** = 
p < 0.01; one-way ANOVA). 
 
 
4.6.2. The genetic lack of Htr5b in Rett mice improves breathing 
Although MeCP2 deficient mice vary in their onset of symptoms, almost all 
individuals display respiratory disturbances with phases of breathing arrests at P40. 
The most decisive question was whether the pathological sustained high expression 
of 5-HT5B in the VRG at this stage is responsible for the breathing disturbances in the 
Rett mouse. To address this question the double-ko mouse was characterized for 
breathing. Therefore, the working heart brainstem preparation (WHBP) was used to 
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analyze phrenic nerve activity (fig. 4.19A). As a measure for breathing irregularity the 
coefficient of cycle variation between consecutive rhythmic bursts was calculated (fig. 
4.19B, C). As expected breathing irregularity was significantly increased in the Rett 
mouse in comparison to wt. The coefficient of variation increased from 7.76 ± 1.59% 
(wt) to 44.93 ± 12.88% (Mecp2-/y, p < 0.05), but was significantly reduced in the 


















Figure 4.19. Improved breathing of double-ko mice. 
(A) Schematic representation of the principle of the working heart brainstem preparation. (B) 
Representative recordings of integrated phrenic nerve activity (∫PNA) of wild type (wt, black trace), 
Mecp2 knockout (Mecp2-/y, red trace), or double-knockout (Mecp2-/y;Htr5b-/-, blue trace) mice. (C) The 
bar diagram represents the coefficient of burst interval variation (CV) as a measure for breathing 
irregularities (n = 5). Breathing irregularities were high in the Mecp2-/y and low in wt and Mecp2-
/y;Htr5b-/- mouse. Asterisks indicate significance (* = p < 0.05; one-way ANOVA). 
 
4.6.2.1. Improvements of the breathing rhythm in double-ko mice in vivo 
Finally, the results from WHBP studies were verified in vivo using plethysmography 
of conscious fully intact animals (fig. 4.20A). Respiratory arrests longer than 1 s, 
which were frequent in the Rett mouse, were reduced in the double-ko mouse 
(Mecp2-/y vs. Mecp2-/y;Htr5b-/-: 5.3 ± 2.6 vs. 0.5 ± 0.4; fig. 4.20B). In wt as well as in 
Htr5b-/- no respiratory arrests were observed. The breathing frequency (4.20C), which 
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was reduced in the Rett mouse (4.60 ± 0.36 Hz) was significantly higher in the 
double-ko mouse (6.23 ± 0.41 Hz, p < 0.05) and normalized when compared to wt 
(6.69 ± 0.36 Hz, n.s.). The breathing irregularity score (fig. 4.20D) of double-ko 
mouse (0.33 ± 0.03) was reduced in comparison to Rett mice (0.46 ± 0.06), but was 
further decreased in Htr5b-/- (0.28 ± 0.03) and wt mice (0.24 ± 0.02).  
Overall, breathing analysis in situ and in vivo revealed less irregularity in double-ko 
mice in comparison with Rett mice. Some of the parameters even showed 
























Figure 4.20. Comparison of breathing rhythm of wt, Mecp2-/y and Mecp2-/y;Htr5b-/- mice in vivo.  
(A) Traces show representative plethysmographic recordings of conscious fully intact animal models: 
wt (n = 9), Mecp2-/y (n = 10), Mecp2-/y;Htr5b-/- (n = 11) or Htr5b-/- (n = 7) mice. Bar diagrams illustrate 
mean value and SEM of (B) breathing arrests exceeding 1 s, (C) breathing frequency, and (D) 




4.6.3. Improvement of physical condition of Mecp2-/y;Htr5b-/- double-knockout 
mouse 
Besides irregular breathing visible symptoms of Mecp2-/y mice are a shorten life 
span, hind limb clasping, and bad generally physical condition (Guy et al., 2001), 
which might be a result of early onset of chronic hypoxia and ischemia. Particular 
physical and molecular parameters, which are known to be altered in Mecp2-/y mice, 
were tested for improvement (fig. 4.21). Determination of the hematocrit value, a soft 
indicator for hypoxia, which is known to be increased in MeCP2 deficient mice 
(Fischer et al., 2009), was significantly reduced in double-ko mice (Rett vs. double-
ko; 0.530 ± 0.005 l/l vs. 0.446 ± 0.016 l/l; p<0.0001) and was comparable with wt 
(0.435 ± 0.005 l/l). The bodyweight, which was considerably reduced in Rett mice 
was significantly increased in double-ko mice (Rett vs. double-ko; 12.47 ± 0.72 g vs. 
17.77 ± 0.68 g, p < 0.0001) and almost normalized compared to wt (20.60 ± 0.56 g). 
Htr5b-/- mice (19.06 ± 1.12 g) did not differ in their bodyweight in comparison with wt.  
The improved physical parameters in double-ko mice in comparison with Rett mice 
were accompanied by a longer survival (fig. 4.21C). The median survival of double-
ko mice was as twice as high compared to Rett mice (Rett mice vs. double-ko; 40 vs. 
80 days; p = 0.0006). Although most of double-ko mice displayed less gait apraxia, 










Fig 4.21. Comparison of physical parameters between Rett and double-ko mice. 
(A) Bar diagram represents mean value and SEM of the hematocrit value from wt (n = 6), Mecp2-/y (n 
= 7), and Mecp2-/y;Htr5b-/- (n = 5) mice at P40 ± 2 (**** = p ≤ 0.0001; one-way ANOVA). (B) Bar 
diagram shows mean value and SEM from bodyweight measurements of wt (n = 17), Mecp2-/y (n = 
17), Mecp2-/y;Htr5b-/- double-knockout mice (n = 15), and male Htr5b-/- mice (n = 7) at P40 ± 2 (* = p ≤ 
0.05; **** = p ≤ 0.0001; one-way ANOVA). (C) Survival plot of Mecp2-/y (n = 37) vs. Mecp2-/y;Htr5b-/- 




Taken together, the physical condition of double-ko mice was obviously improved at 
P40. They were larger in their body size and appeared stronger and healthier 
compared to Rett mice (fig. 4.22). The improved fit was also manifested by the 
observation that female Mecp2-/+;Htr5b-/- mice were able to rear their pups, whereas 





















Figure 4.22. Appearance of wt, Rett, and double-ko mice.  




4.7. Pharmacological treatments  
To confirm the hypothesis that low cAMP concentrations in the VRG caused by the 
pathological high 5-HT5B expression are responsible for breathing disturbances a 
series of pharmacological treatments were performed using the WHBP. To determine 




In wt as well as in double-ko mice, a systemic cAMP reduction by administration of 
the protein kinase A inhibitor Rp-cAMP (0.2 - 0.4 µM) induced a disturbed Rett-like 
respiratory phenotype (fig. 4.23) with phases of breathing arrests. The CV of wt mice 
was significantly increased from 7.76 ± 1.59% to 41.12 ± 7.01%; p < 0.05). In double-
















Figure 4.23. Systemic effects of cAMP reduction on the respiratory rhythm pattern. 
The traces show representative recordings of integrated phrenic nerve activity (∫PNA) in wt and 
Mecp2-/y;Htr5b-/- mice before (control, black trace) and after systemic reduction of cAMP by application 
of 0.4 µM Rp-cAMPs (red trace). The bar diagrams on the right show mean value and SEM of the 
coefficient of cycle variation (CV) as a measure for breathing irregularity (n = 3). In both genotypes an 
increase of CV was observed after systemic drug application. Asterisks indicate significance (* = p < 
0.05; paired t-test). 
 
In contrast systemic augmentation of cAMP by administration of 1 µM of the adenylyl 
cyclase activator forskolin rescued a regular breathing rhythm in the Rett mouse (fig. 
4.24). The CV between rhythmic bursts of the phrenic nerve decreased from 44.93 ± 
12.88% to 12.21 ± 0.61%; p < 0.05, whereas a further decrease of cAMP by systemic 
application of the specific 5-HTR1A agonist 8-OH-DPAT even deteriorated the 
respiratory rhythm. The CV of consecutive bursts increased from 39.87 ± 8.75% to 




















Figure 4.24. Systemic effects of cAMP on the breathing rhythm of Rett mouse. 
The traces show representative recordings of integrated phrenic nerve activity (∫PNA) in Mecp2-/y mice 
before (control, black trace) and after increase of cAMP by application of 1 µM forskolin or decrease of 
cAMP by treatment with 0.2 - 0.4 µM 8-OH-DPAT (red trace). The bar diagram on the right shows 
mean value and SEM of the coefficient of cycle variation (CV) as a measure for breathing irregularity 
(n = 3). Elevation of cAMP led to an improved breathing rhythm, whereas breathing irregularities were 
augmented after cAMP reduction (* = p < 0.05; paired t-test).  
 
 
Augmentation of the intracellular cAMP concentration improved respiratory network 
activity in Rett mice, which might open novel strategies to treat breathing 

















Disturbed breathing is one of the most devastating symptoms of the Rett syndrome 
(RTT), which is caused by various mutations in the MeCP2 gene encoding the 
transcription regulator Methyl-CpG binding protein 2 (MeCP2). Besides other 
breathing irregularities, patients suffer from recurring life threatening breathing 
arrests lasting longer than 45 sec, which are supposed to be responsible for up to 
25% of sudden death (Kerr et al., 1997; Julu et al., 1997). Similar to human patients, 
mice, which carry a knockout in the Mecp2 gene, display arrhythmic breathing with 
onset at approximately postnatal stage 35 (Guy et al., 2001; Viemari et al., 2005; 
Ogier & Katz, 2008; Roux et al., 2008; Zanella et al., 2008). 
In mammals, the three-phase breathing rhythm originates from a neuronal network 
located in the lower brainstem, in which the pre-Bötzinger complex (pre-BötC) that 
belongs to the bilaterally located ventral respiratory group (VRG) is of significance for 
respiratory rhythm generation. Within this network, reciprocal glycinergic inhibition 
between antagonistically connected neurons and serotonergic modulation is relevant 
for the maintenance of regular breathing rhythm (Richter et al., 2003).  
 
 
5.1. Altered gene expression in the VRG of MeCP2 deficient mice 
 
5.1.1. MeCP2 expression and its role in the brainstem during development 
MeCP2 is predominantly expressed in post-mitotic neurons but is also essential 
during embryonic development (Tate et al., 1996). The developmental gene 
expression patterns correlate with the time course of neuronal differentiation and is 
closely linked to synaptogenesis (Shahbazian et al., 2002; Jung et al., 2003; 
Martinowich et al., 2003; Chen et al., 2003). Detailed spatial and temporal MeCP2 
expression analysis in mice brains using IHC and IF, Shahbazian and colleagues 
demonstrate that the protein first becomes evident at embryonic stages in distinct 
regions of the spinal cord and the brainstem (Shahbazian et al., 2002). In the mature 
brain at 19 weeks MeCP2 is expressed strongest in the cerebellum, cortex, 
hippocampus, and olfactory bulb.  
To estimate the importance of MeCP2 on development of the brainstem and the 
respiratory network, the protein level was measured at P7, P15, P21, and P40 
quantitatively. Additionally, mRNA level was measured specifically in the VRG. In 
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both cases Mecp2 mRNA and MeCP2 protein revealed high levels at early state P7 
and late state P40, whereas in intermediate states the level of mRNA and protein 
was significantly lower. Brainstem immaturity and developmental alterations in 
various neurotransmitter systems have been reported for both RTT patients as well 
as for MeCP2 deficient mice (Saito et al., 1999; Paterson et al., 2005; Julu et al., 
1997a; Julu et al., 1997b; Kerr et al., 1999; Smeets et al., 2006). Although MeCP2 
deficient mice show a reduction in their brain size, gross morphological alteration in 
the brainstem has not been reported so far (Ogier & Katz, 2008; Santos et al., 2010). 
Similar to humans, breathing irregularity in Rett mice has not been described in early 
periods of development, but becomes obvious not before P35, when MeCP2 returns 
to higher levels in wt mice. Hence, it was concluded that lack of MeCP2 has an 
impact on gene expression at this stage. A similar high level at P7, however, did not 
reveal an impact on breathing disturbances.  
 
5.1.2. Glycinergic and serotonergic components  
Developmental gene expression of the glycinergic and serotonergic systems were 
analyzed in the VRG using q-PCR. Gene expression of glycinergic components was 
not deregulated at the RNA level in the VRG of MeCP2 deficient mice, whereas three 
of 14 genes associated with the serotonergic system, the dopa decarboxylase (Ddc) 
and the serotonin receptors 1D (Htr1d) and 5B (Htr5b), were significantly up-
regulated. This corresponds with the common concept classifying MeCP2 exclusively 
as a transcriptional repressor. This idea refers to the observation that MeCP2 binds 
to methylated cytosines inhibiting gene expression in vitro (Lewis et al. 1992; 
Meehan et al., 1992; Nan et al., 1997) and was supported by discoveries that MeCP2 
is able to interact with several co-repressors including Sin3A, cSki, CoREST, and 
NcoR initiating heterochromatin formation by recruitment of histone deacetylases 
(HDACs) (Nan et al., 1998; Kokura et al., 2001; Ballas et al., 2005). The Ddc has 
been shown to be up-regulated also in other brain regions including the cortex, 
cerebellum, and midbrain (Urdinguio et al., 2008). Moreover, Ddc was identified as 
direct target of MeCP2 by chromatin immunoprecipitation (ChIP) assay.  
In the present study, we also found the serotonin receptor (5-HTR) 2C to be 
repressed in MeCP2 deficiency, which may result from secondary effects. Several 
studies investigating global gene expression with cDNA microarray analysis found 
that the majority of genes were down-regulated in the absence of MeCP2, in which 
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most of the identified genes showed only moderate alterations (> 1.5-fold) (Jordan et 
al., 2007; Urdinguio et al., 2008; Ben-Shachar et al., 2009). Integrated epigenomic 
analysis revealed that 63% of MeCP2-bound promoters are transcriptionally active 
(Yasui et al., 2007). Furthermore, several genes are activated directly by MeCP2 via 
direct interaction with the transcriptional activator cAMP responsive element binding 
protein 1 (CREB1) (Chahrour et al., 2008).  
Among the dysregulated genes that we identified, Htr5b up-regulation was strongest 
with 70-fold higher mRNA expression rate in the VRG of MeCP2 deficient mice in 
comparison with wt. Such high differences of gene expression in the VRG have not 
been reported so far. Immunohistochemical analysis confirmed the results at the 
protein level showing that the 5-HTR5B up-regulation particularly includes the pre-
BötC, which is vital for respiratory rhythm generation in mammals.  
The temporal coincidence of disturbed breathing functions and the dramatic up-
regulation of Htr5b through missing repression by MeCP2 in Rett mice indicates that 
this gene is a suitable target for direct control by MeCP2 and for further investigations 
of its role in the control of breathing. 
 
 
5.2. Epigenetic control of 5-HTR5B in the VRG 
First evidence that MeCP2 directly represses Htr5b gene expression in the VRG is 
based on the observation that both genes showed reciprocal developmental profiles 
in wild type mice (fig. 4.8).  
 
At developmental stages when MeCP2 expression was high, Htr5b expression was 
suppressed, whereas high Htr5b levels were observed when MeCP2 was low. 
However, this does not explain the results at P7 when MeCP2 is elevated. Hence, 
Htr5b should be up-regulated in MeCP2 deficient mice. In contrast to P40, however, 
there were no differences in Htr5b mRNA expression between Mecp2-/y and wt mice 
at P7.   
Moreover, with exception of the cortex, no Htr5b dysregulation were found in other 
brain regions (fig. 4.4). Comparable results have been reported for other genes, 
which are under direct control of MeCP2. For example, the S100 protein S100a9 was 
found to be up-regulated in the cortex and in the midbrain, but not in the cerebellum 
(Urdinguio et al., 2008).  
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Such regulatory differences can be explained either by developmental and brain-
region specific posttranslational modifications of MeCP2 and/or by specific 
expression of interacting co-repressor proteins.  
Several posttranslational modifications have been reported, such as phosphorylation 
at several serine (S) sites (e.g. S-80, S-229, and S-421), acetylation, and 
ubiquitylation, which affects the binding properties of MeCP2 to DNA and interaction 
partners, such as the co-repressors Sin3A and HP1 (Tao et al., 2009; Chen et al., 
2003; Zhou et al., 2006; Gonzales et al., 2012; Cohen et al., 2011; Zocchi & 
Sassone-Corsi, 2012). Zhou and colleagues demonstrated that phosphorylation at 
serine-421 is specific for brain tissue. However, the authors did not distinguish 
between different regions.  
As MeCP2 binds specifically to methylated DNA, another explanation is a region and 
developmental specific methylation pattern, which already has been shown for 
various genes including the serotonin receptor 2A. For this receptor the methylation 
pattern of the promoter is different between cortex and cerebellum (Ladd-Acosta et 
al., 2007). 
 
Using ChIP procedure we demonstrated an effective binding of MeCP2 to the 
proximal Htr5b promoter in the VRG at P40 (fig. 4.9). However, we could not define a 
specific binding region. We rather found a ubiquitous binding throughout the +5.5 kb 
promoter region, which was enriched at about +4.7 kb. Before MeCP2-specific DNA 
precipitation, the DNA was sheared into smaller fragments between 1,000 and 1,400 
bp in a random fashion, which leads to a statistical distribution of analyzed loci in a 
subsequent q-PCR. However, there is evidence that MeCP2 could be a more global 
regulator and might be able to bind abundantly to almost all single methylated CpG 
sites throughout the whole chromatin (Guy et al., 2011), but seems to be more 
effective by adjacent A/T bases rich regions (AT ≥ 4) (Klose et al., 2005). Such motifs 
are ubiquitously present in the Htr5b promoter.   
By means of Atf7-/- knockout mouse it has been shown that Htr5b is subject to 
epigenetic control (Maekawa et al., 2010) and was found to be strongly up-regulated 
specifically in the dorsal raphé nuclei of the brainstem.  
However, there could not be found any information indicating Htr5b alteration in the 
VRG. Interestingly, similar to the results of this study, Maekawa and colleagues did 
not find any differences in mRNA expression in other brain regions, neither in the 
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hippocampus, the nucleus habenula, nor the nucleus olivaris inferior. The authors 
demonstrated that ATF-7 binds directly to cAMP responsive element (CRE) DNA 
sites at three places/sites in the proximal Htr5b promoter to inhibit gene expression 
by recruiting the methyltransferase HMTase that is part of the EST complex 
mediating methylation histone H3-K9 trimethylation. MeCP2 is able to recruit histone 
deacetylases (HDAC) by means of the co-repressor Sin3A, which mediates 
deacetylation of histones (Nan et al., 1998). Both histone modifications mediate 
heterochromatin formation, which is closely linked to gene silencing (Kass et al., 
1997; Grunstein, 1997; Laherty et al., 1997; Hassig et al., 1997). Atf7-/- null mice 
displayed abnormal behavior, such as anxiety-related attitude and abnormalities in 
the sensomotoric system (Maekawa et al., 2010). These to characteristics are 
common features in Rett syndrome. However, there are no breathing disturbances. 
Furthermore, it was demonstrated that ATF-7 became phosphorylated when mice 
were exposed to isolation stress. Phosphorylation by the map kinase 14 (MAPK14) 
led to dissociation of ATF-7 from the CRE binding site. Same effects were observed 
in vitro when cells were exposed to various kinds of stress.  
In our study Mapk14 and Atf7 mRNA expression did not show any differences in the 
VRG of Rett mice. However, it is most likely that Rett mice also suffer from different 
kinds of stress. Both effects, lack of MeCP2 repression and stress-dependent 
dissociation of ATF-7 from the Htr5b promoter may be an explanation for the 
tremendous Htr5b up-regulation in the VRG, which could be additionally increased by 
CREB1 as the chromatin structure is less dense and CRE is accessible to the 
























Figure 5.1. Hypothetical model of Htr5b regulation in the VRG 
(A) Under normal conditions ATF-7 binds to the cAMP responsive element (CRE, marked in red) and 
recruits the methyltransferase HMTase, which leads to methylation of histones. MeCP2 binds methyl-
CpG-dependend to various regions within the Htr5b promoter and recruits the histone deacetylases 
HDAC1 and HDAC2 by means of the co-repressor Sin3A, which results in deacetylation of histones. 
Both histone modifications lead to heterochromatin formation and to silencing of the Htr5b gene.  
(B) The absence of the global regulator MeCP2 in Rett mice most likely results in cell stress, which 
leads to phosphorylation (P) and to dissociation of ATF-7 from the CRE sites. As a result the 
chromatin structure is opened and CRE is accessible to CREB1 and other transcription activators to 
induce Htr5b mRNA expression. 
 
Under normal conditions of wt mice, high 5-HTR5B protein expression was observed 
in the inferior olive and in the nucleus raphé obscurus, which is in accordance with in 
situ hybridization experiments showing high level of Htr5b mRNA in these brainstem 
regions (Serrats et al., 2004; Matthes et al., 1993). Other brain regions with strong 
Htr5b mRNA expression such as the CA1 region of the hippocampal formation, the 
entorhinal cortex, and the habenula were not tested for protein expression.  
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Furthermore, in contrast to the phylogenetically related 5-HTR5A, which has been 
shown to be predominantly expressed in astrocytes (Carson et al., 1996), we found 
5-HT5B protein expression only in neurons.  
To date, however, it is still unclear whether the strong up-regulation of 5-HT5B in the 
VRG also affects astrocytes.   
 
 
5.3. 5-HTR5B - A classical serotonin receptor? 
 
5.3.1. 5-HTR5B expression in men 
Immunohistochemical analysis of human brainstem sections with a homemade 
antibody revealed strong evidence that 5-HTR5B is also expressed in humans, 
because of the strong reactivity in the inferior olive (IO), where the protein is also 
strongly expressed as in rodents. This is in accordance with reports describing Htr5b 
mRNA to be abundantly expressed in the IO of rat and mouse (Serrats et al., 2004; 
Matthes et al., 1993).  
Comparison of the protein sequence indicated that the antibody epitope, which is 
derived from the C-terminal domain of the receptor, is 100% conserved among 
mouse, rat, and human. In all species the Htr5b gene consists of two exons. 
Sequence analysis of the human HTR5B gene, however, revealed insertions and 
nonsense mutations in its 5’-region after the putative start codon within the first exon, 
which disrupts the coding sequence (cds) failing to encode a functional protein 
(Grailhe et al., 2001). Nevertheless, using q-PCR the authors verified Htr5b mRNA 
expression also in human brain tissue. Sequence analysis among mouse, rat, rabbit, 
and human revealed a highly conserved second ATG within the last part of the 
second exon, which is in frame with the cds. Expression from this ATG would lead to 
an N-terminal-truncated protein. The applied antibody, which is directed against the 
very end of the C-terminal domain of the receptor, could explain the immunoreactivity 
in the human inferior olive. Another possibility would be the presence of an 
alternative first exon. However, chromosome mapping of the HTR5B/Htr5b gene by 





5.3.2. 5-HTR5B is truncated 
The hypothesis that 5-HTR5B is truncated was supported by western blot analysis. 
Surprisingly, the immunoblot revealed for both rat and mouse brainstem lysates a 
specific signal at 22.5 kDa, which was smaller than the expected relative molecular 
mass of 41 kDa for the full-length protein (fig. 4.11). This correlated exactly with the 
predicted mass of the protein encoded by the second ATG. There was no evidence 
for a shortened transcript. Western blot analysis did not reveal a full-length 5-HTR5B 
protein in both species, although the full-length open reading frame from brainstem 
cDNA could be cloned. Another evidence for the truncation was provided by 
sequence comparison showing that the protein sequence among species was highly 
conserved after the second ATG, whereas the 5’-region was not, which indicates an 
evolutionary preserved function. We consider that the truncation of the protein might 
result from the posttranslational cleavage by a protease. However, human protein 
expression and identification of a specific second ATG also argues for truncation as a 
result of expression from the alternative start codon. The exact molecular mechanism 
of the ATG switch could not be defined yet. 
Originally, the 5-HTR5B groups with the 5-HTR5A to a distinct subclass of G-protein 
coupled serotonin receptors (GPCRs). Both receptors share 70% sequence 
homology (Hoyer et al., 2002), but only 23 - 34% homology to other 5-HT receptors 
(Plassat et al., 1992). Detailed protein analysis revealed that the shortened 5-HTR5B 
is truncated by the first 3 of 7 transmembrane domains (TM) including the serotonin-
binding site. The missing ligand-binding site of 5-HTR5B could explain the results of a 
pharmacological study using radio-ligand binding assay (Matthes et al., 1993), in 
which there was no binding of various serotonergic radio-ligands, such as [3H]5-HT, 
[3H]8-OH-DPAT, or 125I-cyanopindolol, in membrane fractions of Htr5b (full-length) 
transfected COS-7 cells were detectable. However, they found a binding of 125I-LSD, 
a well-known activator of serotonin receptors, which might be a result of an 




5.3.3. Htr5 group show partially unusual protein localization 
Overexpression of fusion constructs in murine N1E-115 neuroblastoma cells showed 
an unexpected clustered intracellular expression pattern for both variants (4.12), 
which resembled the 5-HTR5B immunoreactivity observed in human tissue (fig. 4.10). 
Contrary to 5-HTR5B, 5-HTR1A and 5-HTR7 showed an expected strong cell 
membrane expression pattern (fig. 4.12 and 4.16). As N1E-115 cells were 
transfected under identical conditions, and all fusion constructs were generated in an 
identical manner, the unusual intracellular expression of 5-HTR5B does not seem to 
result from overexpression. 
Trafficking and stability of cell membrane localization of GPCRs is affected by 
various posttranslational modifications such as palmitoylation and glycosylation 
(Goddard and Watts, 2012). Recently, it has been shown that cell surface expression 
of the related 5-HTR5A is affected by specific N-glycosylation on asparagine-6 and 
asparagine-21 in the N-terminal part of the protein (Dutton et al., 2008). The receptor 
remained intracellular either when both asparagine residues were deleted, or 
N-glycosylation was inhibited by tunicamycin.  
The putative full-length 5-HT5B protein contains an asparagine residue on position 5 
in its amino acid sequence, which is absent in the truncated protein. However, 
expression of the full-length 5-HTR5B exhibited the same intracellular localization as 
the truncated form.  
Dutton and co-workers also observed that a large percentage of the non-mutated 
5-HTR5A was located intracellularly, which is in accordance with our findings for this 
receptor subtype.  
Cell surface expression can also be affected by many co-factors, such as 
cytoplasmic PDZ proteins [named for its structural domain shared by the 
postsynaptic density protein (PSD95)] (Romero et al., 2011), GPCR-associated 
sorting proteins (GASPs) (Magalhaes et al., 2012), Homer proteins (Kammermeier & 
Worley, 2007), regulator of G-protein signaling (RGS) (Sethakorn et al., 2010), and 
also small G-proteins such as Rab GTPases (Magalhaes et al., 2012).  
This is only a selected number of protein classes, which have either direct or indirect 
influence on retaining GPCRs at the cell membrane. For example, the C-terminal 
region of 5-HTR2A has been shown to interact with the multiple PDZ protein-1 
MUPP1, which effectively affects 5-HTR2A localization in spines and dendrites (Xia et 
al., 2003; Jones et al., 2009). Interaction between 5-HTR2C and MAGUK p55 
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subfamily member 3 (MPP3) increased cell membrane stability, whereas PSD-95 
showed opposite effects (Gavarini et al., 2006). Specific interaction partner of 5-
HTR5B may be absent in N1E-115 cells, which could avoid effective trafficking to the 
cell membrane. However, electron microscopy of 5-HTR5B-immunogold staining on 
brainstem sections of wild type mice confirmed the results of in vitro experiments as 
we detected strong signals associated with membranes of vesicular and tubular 
structures, whereas cell membrane expression was not observed (fig. 4.14). 
  
Even though we cannot fully exclude that 5-HTR5B is expressed on the cell surface in 
other brain regions, we propose that the truncated 5-HTR5B has lost its function as a 
classical serotonin receptor. Hence, we renamed the protein to 5-HT5B. 
 
The secretory pathway of GPCRs to their destination on the cell membrane begins 
with the co-translational integration into the endoplasmic reticulum (ER) membrane, 
which either occurs in a signal-dependent or independent manner by means of the 
signal recognition particle (SRP) and the translocon (mainly consisting of the protein-
conducting channel protein Sec61) (Alken et al., 2005). The latter is the case for the 
majority of GPCRs (90 - 95%) (Wallin & von Heijne, 1995). The ER plays important 
role in the correct folding of proteins. 50% of all newly synthesized proteins are 
retained in the ER due to failing of quality control criteria (Ellgaard et al., 1999).  
A major part of meanwhile identified truncated GPCRs, which are mostly splice 
variants of their wt receptor form, are also retained predominantly in the ER (tab. 
5.1). 
5-HT5B seemed to pass the ER because the majority of 5-HT5B protein is co-localized 
with RAB7, which is a marker for the (late) endosomal compartment. We did not 
observe any differences in the localization of both 5-HT5B variants. Hence, it was 
concluded that lack of the N-terminal part in the truncated protein cannot be 
causative for the endosomal localization. The (late) endosomal compartment seems 
to be rather associated with desensitization, which describes the β-arrestin-mediated 
internalization of GPCRs after activation. This is a common mechanism to switch off 
the signaling cascade. From the (late) endosomal compartment, GPCRs are either 
degraded in the lysosome by compartment fusion or recycled and restored to the cell 





Table 5.1. Selection of identified truncated GPCRs with localization and their influence of   
corresponding wild type receptors.  
 
The truncated variant of receptors often dominates (dom) the localization of the wild type form.  
Receptor Name/truncation Localization Dom/neg Reference 
α1A-adrenoceptor 6TM ER Yes Seck et al., 2005 
Chemokine receptor 5  Ccr5Δ32, 5TM ER Yes Benkirane et al., 
1997 
Dopamine receptor (D3) D3nf, 5TM ER Yes Karpa et al., 2000 
Gastric inhibitory 
polypeptide receptor 
4TM ER Yes Harada et al., 2008 
Ghrelin receptor GHS-R1b, 5TM ER Yes Leung et al., 2007 
Gonadotropin-releasing 
hormone receptor 
5TM  Yes Grosse et al., 1997 
Histamine receptor rH3R  Yes Bakker et al., 2006 
Nociceptin receptor 4TM CM Yes Xie et al., 2000 
Somatostatin receptor 5 4TM ? No Cordoba-Chacon et 
al., 2010 




5.4. The physiological role of 5-HT5B 
The role of the resident localization of 5-HT5B into endosomes remains obscure. 
Based on further findings we propose two hypotheses regarding interaction of 5-HT5B 
with other 5-HT receptors and influence of 5-HT5B on cAMP signaling. 
 
 
5.4.1. 5-HT5B proteins affect localization of serotonin receptors 
In the past two decades numerous studies were set up, which described homo-, 
hetero-, and oligomerization of GPCRs. A well-known example is the GABAB 
receptor, which is selectively activated by the inhibitory transmitter γ -aminobutyric 
acid (GABA). The receptor is active only as heterodimer consisting of GABABR1 and 
GABABR2 monomers (Angers et al., 2002; White et al. 1998; Kaupmann et al., 
1998). In rare cases hetero- and homodimerization were also found for serotonin 
receptors, e.g. homodimerization of the Gαq-coupled 5-HTR2C has been reported to 
be important for its signaling function (Herrick-Davis et al., 2005). Homo- and 
dimerization have been described also for other serotonin receptors, but 
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preferentially for class 1, such as 5-HTR1B, 5-HTR1D, and 5-HTR1A (Xie et al., 1999; 
Renner et al., 2012; Lukasiewicz et al., 2007). 5-HTR1A is able to form homodimers 
and heterodimers with 5-HTR7 and even with the adenosine A2A receptor (Renner et 
al., 2012; Lukasiewicz et al., 2007). However, there was no information about 
interaction of 5-HT receptors with 5-HTB proteins. Our cell experiments showed that a 
major part of the 5-HTR1A was removed from the cell membrane and retained within 
the cell in presence of 5-HT5B. This effect on 5-HTR1A was equal for both variants of 
5-HT5B (fig. 4.16A). However, we cannot exclude, that this finding was an artifact due 
to overexpression. We did not observe such effect concerning 5-HTR7 (fig. 4.16B). 
Otherwise, no co-localization was observed when 5-HTR1A and 5-HTR5A were co-
expressed (fig. 4.16A). Therefore, we assume that 5-HTR1A-5-HT5B interaction is 
specific. For clarification we plan further experiments, such as co-
immunoprecipitation, Förster resonance energy transfer (FRET), or surface plasmon 
resonance (SPR), which might provide more evidence for the observed 
phenomenon. 
Similar effects were reported recently for the ghrelin receptor (GH-R1a). Due to direct 
interaction with a naturally occurring truncated splice variant (TM-I - TM-V), the 
receptor is retained within the ER (Howard et al., 1996; Leung et al., 2007; Chow et 
al., 2012). Other examples are listed in table 5.1. Similar to our data, most of the 
identified truncated GPCRs show a dominant-negative effect on the localization of 
their corresponding wild type forms. Thus, truncated receptors may play an important 
role in the regulation of GPCR activity and the signaling process (Magalhaes et al., 
2012; Milligan, 2010).  
 
5.4.2. 5-HT5B and its role in cAMP signaling 
Activation of GPCRs results in a conformational change of the bound heterotrimeric 
G-protein induced by a nucleotide exchange, in which GDP is replaced by a GTP in 
the Gα-subunit. This leads to a dissociation of the Gα-subunit from the Gβγ-dimer. 
Depending on the class of the Gα-protein various pathways can be switched on. 
Using [35S]GTPγS binding assay, we identified the inhibitory Gαi3-protein, which 
couples to the phylogenetically related 5-HTR5A (Francken et al., 1998), as the 
preferred G-protein binding partner of 5-HT5B. Gαi3-proteins inhibit adenylyl cyclases 
(ACs) occluding cAMP formation. This is in accordance with our results showing that 
in Htr5b transfected N1E-115 cells, cAMP-concentration was reduced by 50% 
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compared to MOCK control. For this effect no serotonin stimulation was needed, 
which indicates that there is an intrinsic constitutive activity of 5-HT5B. However, an 
additional contribution of other co-factors cannot be excluded.  
The cAMP-reducing properties of 5-HT5B-proteins were also demonstrated in in vivo. 
The pathologically strong expression of 5-HT5B in the VRG of MeCP2 deficient mice 
at P40 was accompanied with low level of cAMP in this region. This is in line with 
recent studies showing a decreased level of in vitro-cultured brainstem slices 
including the pre-BötC (Mironov et al., 2011). A consistent finding was that double-ko 
(Mecp2-/y;Htr5b-/-) mice at P40 showed a normalized cAMP level, which 
demonstrated that 5-HT5B-proteins were responsible for the reduction. 
The observation of the putative constitutive activity of 5-HT5B and the predominantly 
endosomal localization raises the question of the physiological role, which is closely 
linked with potential regulatory targets. 
Cyclic AMP is produced by adenylyl cyclases after stimulation via Gαs-proteins 
through GPCRs. To date, in mammals at least 10 different AC isoforms have been 
identified (Billington & Hall, 2012). Nine of them represent large membrane integrated 
proteins (ACtm) with a relative molecular mass of 120 to 140 kDa. Another soluble 
isoform (ACs) has been isolated first from cytosolic extract of rat testis, but is also 
present in other tissues including the brain (Braun & Dods, 1975; Sinclair et al., 
2000). Cyclic AMP is the classical second messenger regulating a vast number of 
signaling processes either directly in case of cyclic nucleotide-gated channels 
(CNGs) or mediated by cAMP-dependent protein kinase A (PKA). Uncountable target 
proteins of PKA have been reported. Hence, cAMP is directly and indirectly involved 
in almost all physiological cell processes including cell excitability, metabolism, gene 
regulation, cell division, differentiation, and apoptosis (Francis & Corbin, 1994).  
Therefore, it is important for cells to keep different cAMP signaling pathways 
separated. This is maintained by scaffold and anchor proteins, which cohere proteins 
involved in the same pathway, and separation by lipid raft microdomains. However, 
cAMP is soluble and diffusible. If cAMP signals remain uncontrolled and cAMP 
concentrations increase rapidly, all pools of cAMP effectors would have the same 
chance of being activated, which could result in uncoordinated simultaneous 
activation of different pathways. To this end, cells express a defined subset of 
phosphodiesterases (PDEs) that rapidly degrade cAMP, which is an important 
function in the arising concept of cAMP microdomains (Tresguerres et al., 2011). 
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Endosomal Gαi3-coupled 5-HT5B might be engaged in the inactivation of co-
internalized ACs together with GPCRs, and keeping ACs in an inactive state until 
they are restored at the cell membrane. Thus, 5-HT5B proteins might be involved in 























Figure 5.2. Schematic representation of the putative function of 5-HT5B in cAMP signaling. 
Cyclic 3´,5´-adenosine monophosphate (cAMP) is produced by Gαs-activated adenylyl cyclases (ACs) 
upon G-protein coupled receptor (GPCR) stimulation. Cyclic AMP acts directly on cyclic nucleotide-
gated channels (CNGCs) or is indirectly involved, mediated by protein kinase A, in almost all 
physiological processes, such as gene regulation, metabolism, or apoptosis via diverse effectors, such 
as mammalian target of rapamycin (mTOR), mitogen-activated protein kinase 14 (MAK14), or Ras 
related proteins (Rap1/2). To avoid cross-reactions between different cAMP-mediated signaling 
pathways, cAMP is regulated strongly to maintain cAMP microdomains. Therefore, cAMP is degraded 
by soluble phosphodiesterases (PDEs), whereas endosomal 5-HT5B proteins are involved in switching 






5.5. Pathophysiological consequences of 5-HT5B-induced cAMP depression 
Almost all Mecp2-/y mice displayed irregular breathing at P40 in the in situ working 
heart brainstem preparation as well as in in vivo, which was in accordance with 
previous studies of this mouse model (Guy et al., 2001; Stettner et al., 2007; Abdala 
et al., 2010). We demonstrated that the pathologically strong expression in the VRG 
at P40 plays a crucial role in the onset of arrhythmic breathing. In situ and in vivo 
experiments showed a clear improvement of breathing in double-ko mice. There are 
suggestions that the breathing phenotype of Mecp2-/y mice may result from impaired 
synaptic plasticity of the respiratory network caused by altered developmental gene 
expression (Julu et al., 1997; Stettner et al., 2007; Medrihan et al., 2008; Abdala et 
al., 2010). Although expression of GABA receptors is dysregulated at early 
development stage P7, plethysmographic recordings did not show any abnormalities 
in resting ventilation (Medrihan et al., 2008). Additionally, breathing disturbances also 
occurred in mice after Mecp2 was switched off at a later postnatal stage (> P60), 
when the respiratory network is already completely matured (McGraw et al., 2011), or 
were diminished when Mecp2 expression was switched on after P28 (Guy et al., 
2007). The coincidence of the strong dysregulation of 5-HT5B in the VRG together 
with the onset of disturbed breathing in Rett mice was a strong indication for the 
involvement of this protein, which was proved using Mecp2-/y,Htr5b-/- double-ko mice. 
Regular breathing (eupnoea) depends on a coordinated respiratory network activity 
to accurately shape the firing pattern and to control burst termination and phase 
transitions (Richter, 1996; Richter & Spyer 2001). The respiratory network operates 
with a reciprocal organization of antagonistic groups of glutamatergic, GABA-ergic, 
and glycinergic interneurons (Richter et al., 1996), in which the glycinergic control is 
vital for respiratory phase termination (Pierrefiche et al., 1998). A disturbed 
glycinergic transmission is able to cause several breathing abnormalities like hypoxia 
(Richter et al., 1991) and hyperekplexia (Büsselberg et al., 2001). However, in 
Mecp2-/y mice the expression of glycine receptors and transporters at the RNA level 
was not altered in comparison with wt mice at P40, when the respiratory phenotype is 
entirely developed (fig. 4.2). One explanation for the disturbed network function might 
be the coincidence of down-regulation of glycine receptor alpha 3 (GlyRα3), which is 
important for rhythmic breathing and target for Gαi3-dependent phosphorylation 
(Manzke et al., 2010), and up-regulation of 5-HT5B, which also couples to Gαi3-protein 
reducing intracellular cAMP concentration. This presumed involvement of gylcine 
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receptors corresponds with comparable breathing disturbances occurring at the end 
of the 3rd postnatal week in the Oscillator mouse model for hyperekplexia, in which a 
deficient GlyRα1 is expressed (Markstahler et al., 2002; Büsselberg et al., 2001). 
However, to explain the arrhythmic breathing pattern on network level in detail, it is 
indispensable to collect further information about the physiological role of 5-HT5B 
within the cell, its expression in electro-physiologically identified respiratory neurons 
and its effect on signaling pathways. Although the exact mechanism still is unknown, 
the reduced cAMP level in the VRG at P40 is obviously causative for the disturbed 
breathing in Mecp2-/y mice. 
Systemic application of the protein kinase A inhibitor Rp-cAMPs induced a Rett-like 
respiratory phenotype in working heart brainstem preparations (fig. 4.23), whereas 
administration of forskolin, an adenylyl cyclase activator elevating intracellular cAMP 
concentration, rescued a regular central respiratory rhythm in Mecp2-/y mice (fig. 
4.24). The definitive proof that 5-HT5B is truly causal for the respiratory dysfunction in 
Mecp2-/y mice, was demonstrated by means of double-ko mice (Mecp2-/y;Htr5b-/-), in 
which Htr5b was additionally knocked out. It is noteworthy that Htr5b-/- ko-mice, which 
were used for crossbreeding, did not show any respiratory disturbances (fig. 4.20).  
In contrast to Mecp2-/y mice, double-ko mice, which showed a normal cAMP 
concentration in the VRG (fig. 4.18), displayed regular phrenic nerve output activity of 
the respiratory network (fig. 4.19). These findings were confirmed by plethys-
mographic recordings in conscious fully intact animals (fig. 4.20).  
Based on breathing irregularities accompanied with breathing arrests, MeCP2 
deficient mice may be chronically hypoxic and ischemic, which is displayed e.g. by an 
up-regulation of the hypoxia-inducible factor 1 alpha (HIF1α) and an increased 
hematocrit value, which was previously reported (Fischer et al., 2009), and which is 
in accordance with our data. These hypoxic conditions might be reasonable for the 
bad physical condition and the shortened lifespan. This hypothesis is supported by 
double-ko mice exhibiting an almost normalized hematocrit value in comparison with 
wt mice that might be caused by improved oxygen supply.  
Overall, double-ko mice appeared healthier compared to Mecp2 ko mice (fig. 4.22). 
In particular, hematocrit and body weight returned to wild type levels (fig. 4.21), and 




5.6. Pharmacological strategies 
The research for the cause of the origin of breathing disturbances goes hand in hand 
with the development of a potential pharmacotherapy to overcome life-threatening 
breathing arrests in RTT patients.  
Basically, serotonin receptors are potential targets to treat several diseases, such as 
irritable bowel syndrome, anxiety, and depression. However, a treatment directly 
targeting 5-HT5B should be difficult due to its truncation and intracellular localization. 
Activation of 5-HTR1A, e.g. with 8-OH-DPAT or the clinically approved anxiolyticum 
buspirone, is an established strategy to overcome apneustic breathing in several 
diseases, spinal cord injury (SCI), or after pharmacological treatment with opiates 
(El-Khatib et al., 2003; Wilken et al., 1997; Lalley et al., 1994; Richter et al., 1994; 
Dutschmann et al., 2009; Sahibzada et al., 2000; Teng et al., 2003). 
The supposed molecular mechanism begins with cAMP reduction through activation 
of inhibitory G-proteins Giα3, which results in dephosphorylation of the glycine 
receptor subunit α3 due to diminished PKA activity (Manzke et al., 2010). Resultant 
potentiation of glycinergic synaptic inhibition of inspiratory neurons mediated by post-
I-neurons terminates inspiration. Such potentiation of glycinergic synaptic inhibition is 
beneficial during early development of MeCP2 deficient mice, but fades despite low 
cAMP levels when the cAMP-PKA sensitive GlyRα3 is downregulated, a further 
depression of cAMP through activation of 5-HTR1A would remain ineffective. Hence, 
we propose a cAMP-elevating strategy, which is supported by experiments showing 
that systemic cAMP elevation in in vivo-like preparations rescued regular breathing.  
Therefore, it is surprising that treatment with 8-OH-DPAT led to improvement of 
breathing in Mecp2-/y and Mecp2-/+ mice (Abdala et al., 2010). However, this is in 
contrast to our data. We found that apneas in Mecp2-/y mice even become more 
frequent, and the phrenic nerve activity undergoes a dramatic decline after lowering 
cAMP upon systemic 5-HTR1A activation by 8-OH-DPAT. To date, we cannot 




Alternative approaches to improve respiration in Rett mice are summarized in the 
following table 5.2. 
 
 
Table 5.2. Pharmacological treatment of breathing disturbances in mouse models for the Rett 
syndrome 
 
IP = intraperitoneal, Tyrosine kinase receptor B (TrkB), Insulin-like growth factor 1 (IGF-1) 
Substance/drug Application form Mouse 
model 
Target Effect Reference 
Desipramine oral Mecp2-/y norepinephrine 
reuptake blocker 
Yes Zanella et al., 
2008 
Desipramine  IP injection Mecp2-/y norepinephrine 
reuptake-blocker 
Yes Roux et al., 
2007 
Ampakine IP injection Mecp2-/y AMPA receptor 
agonist 
Yes Ogier et al., 
2007 
LM22A-4 IP injection Mecp2+/-  (TrkB) agonist Yes Schmid et al., 
2012 
Active peptide of 
IGF-1 
IP injection Mecp2-/y IGF-1 receptor Yes Tropea et al., 
2009 






Yes Abdala et al., 
2010 








Despite diverse approaches, which seemed to be more or less effective to overcome 
respiratory disturbances in mouse models for the Rett syndrome, there is no reliable 







The present work shows that breathing disturbances in a mouse model for Rett 
syndrome (RTT) arises mainly by dysregulation of a single gene, which encodes for 
the orphan serotonin receptor 5B (5-HTR5B). The lack of MeCP2 repression, which is 
causal for RTT, results directly in high levels of 5-HTR5B in the VRG and adjacent 
regions important for respiratory rhythm generation at postnatal stage 40, which 
coincides with the onset of breathing disturbances in MeCP2 deficient mice. In this 
thesis, it is demonstrated that the receptor is naturally truncated and attached to the 
membrane of endosomes, but retains its ability to bind inhibitory G-proteins Gαi3 that 
reduces intracellular cAMP in a constitutive manner. The pathologically strong 5-
HT5B-protein expression in the VRG of MeCP2 deficient mice results in a persistent 
low cAMP level, which obviously disturbs central breathing rhythm.   
 
The second messenger cAMP affects a broad range of signal transduction cascades 
ranging from alteration of membrane excitability by direct influence on ion channels 
right up to the influence on regulation of gene expression. Accompanied with the 
molecular behavior and peculiar localization of the 5-HT5B protein in endosomes, we 
currently could not identify molecular targets affected by persistent low cAMP 
concentration to explain the breathing disturbances on respiratory network level in 
detail.  
This is complicated by the observation that 5-HT5B proteins affect the localization of 
the serotonin receptor 1A, which plays an important role for the modulation of the 
respiratory rhythm.  
However, showing successful treatment by cAMP elevation in in situ together with 
the proof of 5-HT5B expression in men provide new pharmacological strategies to 
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